{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Converting BEL graphs into inputs for GAT2VEC.\n",
    "\n",
    "## Imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "\n",
    "import bio2bel_phewascatalog\n",
    "from GAT2VEC import paths as gat2vec_paths\n",
    "from networkx import DiGraph, write_adjlist\n",
    "from networkx.relabel import convert_node_labels_to_integers\n",
    "from pybel import from_url, from_path\n",
    "from pybel.dsl import BaseEntity, gene, protein, rna\n",
    "from pybel.struct.mutation.collapse import collapse_to_genes, collapse_all_variants\n",
    "from pybel_tools.assembler.reified_graph import assembler\n",
    "\n",
    "import guilty_phewas.utils as phewas_utils"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Define the file names."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "basedir = 'C:/Users/Mauricio/Thesis/bel_data'\n",
    "url = {    \n",
    "    'tau': 'https://raw.githubusercontent.com/neurommsig/neurommsig-knowledge' + \\\n",
    "           '/master/neurommsig_knowledge/Tau%20protein%20subgraph.bel',\n",
    "    'gsk3': 'https://raw.githubusercontent.com/neurommsig/neurommsig-knowledge/' + \\\n",
    "           'master/neurommsig_knowledge/GSK3%20subgraph.bel',\n",
    "    'alzh': 'https://raw.githubusercontent.com/neurommsig/neurommsig-knowledge/' + \\\n",
    "           'master/neurommsig_knowledge/GSK3%20subgraph.bel'\n",
    "}\n",
    "\n",
    "def get_base_dir(basedir, path):\n",
    "    return os.path.join(basedir, path)\n",
    "\n",
    "def get_local_bel_file(basedir, path):\n",
    "    dir_ = get_base_dir(basedir, path)\n",
    "    return os.path.join(dir_, path + '.bel')\n",
    "\n",
    "def get_struct_file(basedir, path):\n",
    "    dir_ = get_base_dir(basedir, path)\n",
    "    return os.path.join(dir_, path + '_graph.adjlist')\n",
    "\n",
    "def get_attr_file(basedir, path):\n",
    "    dir_ = get_base_dir(basedir, path)\n",
    "    return os.path.join(dir_, path + '_na.adjlist')\n",
    "\n",
    "def get_labels_file(basedir, path):\n",
    "    dir_ = get_base_dir(basedir, path)\n",
    "    return os.path.join(dir_, 'labels_maped.txt')\n",
    "\n",
    "bel = 'alzh'\n",
    "# bel = 'tau'\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "# possible inputs\n",
    "# url = param_dict['url']\n",
    "local = get_local_bel_file(basedir, bel)\n",
    "\n",
    "# Output files \n",
    "struct_file = get_struct_file(basedir, bel)\n",
    "attr_file = get_attr_file(basedir, bel)\n",
    "labels_file = get_labels_file(basedir, bel)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Read and reify a BEL graph."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "ERROR:pybel.parser:C:/Users/Mauricio/Thesis/bel_data\\alzh\\alzh.bel:35457:23 MissingNamespaceNameWarning \"Glycoside hydrolases\" is not in the GFAM namespace\n",
      "ERROR:pybel.parser:C:/Users/Mauricio/Thesis/bel_data\\alzh\\alzh.bel:44994:2 MissingNamespaceNameWarning \"N-terminal domain of APP\" is not in the HBP namespace\n",
      "ERROR:pybel.parser:C:/Users/Mauricio/Thesis/bel_data\\alzh\\alzh.bel:44995:2 MissingNamespaceNameWarning \"N-terminal domain of APP\" is not in the HBP namespace\n",
      "ERROR:pybel.parser:C:/Users/Mauricio/Thesis/bel_data\\alzh\\alzh.bel:44996:2 MissingNamespaceNameWarning \"N-terminal domain of APP\" is not in the HBP namespace\n",
      "ERROR:pybel.parser:C:/Users/Mauricio/Thesis/bel_data\\alzh\\alzh.bel:44997:2 MissingNamespaceNameWarning \"N-terminal domain of APP\" is not in the HBP namespace\n",
      "ERROR:pybel.parser:C:/Users/Mauricio/Thesis/bel_data\\alzh\\alzh.bel:44998:2 MissingNamespaceNameWarning \"N-terminal domain of APP\" is not in the HBP namespace\n",
      "ERROR:pybel.parser:C:/Users/Mauricio/Thesis/bel_data\\alzh\\alzh.bel:48711:2 MissingNamespaceNameWarning \"N-terminal fragment of APP\" is not in the HBP namespace\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Starting nodes 5165\n",
      "Starting edges 17226\n",
      "Nodes after collapse 4722\n",
      "Edges after collapse 16675\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:No converter found for a(CHEBI:\"amyloid-beta polypeptide 40\"), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'line': 149, 'relation': 'isA', 'evidence': 'The statements inside this citation is included to connect two entity types or triples, which will exist as islands/subnetworks in the big model.', 'citation': {'type': 'Other', 'name': 'Connectors', 'reference': '123'}}\n",
      "WARNING:root:No converter found for p(HGNC:APP), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'line': 150, 'relation': 'isA', 'evidence': 'The statements inside this citation is included to connect two entity types or triples, which will exist as islands/subnetworks in the big model.', 'citation': {'type': 'Other', 'name': 'Connectors', 'reference': '123'}}\n",
      "WARNING:root:No converter found for p(HGNC:APP), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'line': 154, 'relation': 'isA', 'evidence': 'The statements inside this citation is included to connect two entity types or triples, which will exist as islands/subnetworks in the big model.', 'citation': {'type': 'Other', 'name': 'Connectors', 'reference': '123'}}\n",
      "WARNING:root:No converter found for p(HGNC:APP), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 5201, 'relation': 'biomarkerFor', 'evidence': 'Our findings support the notion that CSF tau and Abeta(1-42) may be useful biomarkers in the early identification of AD in MCI subjects.', 'citation': {'type': 'PubMed', 'name': 'Mol Psychiatry. 2004 Jul;9(7):705-10', 'reference': '14699432'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'MeSHAnatomy': {'Cerebrospinal Fluid': True}, 'Subgraph': {'Amyloidogenic subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:APP), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 33621, 'relation': 'biomarkerFor', 'evidence': \"The aspartic protease beta-secretase (BACE) cleaves the amyloid precursor protein into a 42 residue beta-peptide, which is the principal biochemical marker of Alzheimer's disease.\", 'citation': {'type': 'PubMed', 'name': 'Structure2005', 'reference': '16216580'}, 'annotations': {'Subgraph': {'Amyloidogenic subgraph': True, 'Beta secretase subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:APP), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\")\n",
      "WARNING:root:  with edge data {'line': 197, 'relation': 'isA', 'evidence': 'We previously showed that beta-amyloid precursor protein (APP) is cleaved not only in the middle of the membrane (gamma-cleavage) but also at novel cleavage sites close to the membrane/cytoplasmic boundary (ε-cleavage), releasing APP intracellular domains (AICDs) 49−99 and 50−99. To learn more about the relationship between gamma- and ε-cleavage, C-terminally truncated carboxyl-terminal fragments (CTFs) of APP, especially CTFs1−48 and 1−49 (the postulated products that are generated by ε-cleavage), were transiently expressed in CHO cells. Most importantly, the cells expressing CTF1−49 secreted predominantly amyloid beta-protein (Abeta) 40, while those expressing CTF1−48 secreted preferentially Abeta42. This supports our assumption that ε-cleavage precedes Αbeta production and that preceding ε-cleavage determines the preference for the final Abeta species. The gamma-secretase inhibitors, L-685,458 and DAPT, suppressed Abeta production from CTF1−49. Regarding Abeta production from CTF1−48, L-685,458 suppressed it, but DAPT failed to do so. A dominant negative mutant of presenilin 1 suppressed the production of Abeta40 and 42 from both CTFs1−48 and 1−49. These data should shed significant light into the mechanism of Abeta production.', 'citation': {'type': 'PubMed', 'reference': '15491160'}, 'annotations': {'TextLocation': {'Abstract': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:APP), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\")\n",
      "WARNING:root:  with edge data {'line': 198, 'relation': 'isA', 'evidence': 'We previously showed that beta-amyloid precursor protein (APP) is cleaved not only in the middle of the membrane (gamma-cleavage) but also at novel cleavage sites close to the membrane/cytoplasmic boundary (ε-cleavage), releasing APP intracellular domains (AICDs) 49−99 and 50−99. To learn more about the relationship between gamma- and ε-cleavage, C-terminally truncated carboxyl-terminal fragments (CTFs) of APP, especially CTFs1−48 and 1−49 (the postulated products that are generated by ε-cleavage), were transiently expressed in CHO cells. Most importantly, the cells expressing CTF1−49 secreted predominantly amyloid beta-protein (Abeta) 40, while those expressing CTF1−48 secreted preferentially Abeta42. This supports our assumption that ε-cleavage precedes Αbeta production and that preceding ε-cleavage determines the preference for the final Abeta species. The gamma-secretase inhibitors, L-685,458 and DAPT, suppressed Abeta production from CTF1−49. Regarding Abeta production from CTF1−48, L-685,458 suppressed it, but DAPT failed to do so. A dominant negative mutant of presenilin 1 suppressed the production of Abeta40 and 42 from both CTFs1−48 and 1−49. These data should shed significant light into the mechanism of Abeta production.', 'citation': {'type': 'PubMed', 'reference': '15491160'}, 'annotations': {'TextLocation': {'Abstract': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:APP), a(CHEBI:\"Heparin binding peptide\")\n",
      "WARNING:root:  with edge data {'line': 66648, 'relation': 'isA', 'evidence': 'Binding to HSPGs requires a heparin/heparan sulfate-binding domain consisting of a stretch of positively charged lysines or arginines on the ligand. Prion protein, beta-amyloid, tau, and alpha-synuclein all have putative heparin-binding domains(25, 44Ã¢â‚¬â€œ46).', 'citation': {'type': 'PubMed', 'name': 'Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47.', 'reference': '23898162'}, 'annotations': {'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:APP), p(HBP:\"APP C-terminally truncated carboxyl-terminal fragments\")\n",
      "WARNING:root:  with edge data {'line': 194, 'relation': 'isA', 'evidence': 'We previously showed that beta-amyloid precursor protein (APP) is cleaved not only in the middle of the membrane (gamma-cleavage) but also at novel cleavage sites close to the membrane/cytoplasmic boundary (ε-cleavage), releasing APP intracellular domains (AICDs) 49−99 and 50−99. To learn more about the relationship between gamma- and ε-cleavage, C-terminally truncated carboxyl-terminal fragments (CTFs) of APP, especially CTFs1−48 and 1−49 (the postulated products that are generated by ε-cleavage), were transiently expressed in CHO cells. Most importantly, the cells expressing CTF1−49 secreted predominantly amyloid beta-protein (Abeta) 40, while those expressing CTF1−48 secreted preferentially Abeta42. This supports our assumption that ε-cleavage precedes Αbeta production and that preceding ε-cleavage determines the preference for the final Abeta species. The gamma-secretase inhibitors, L-685,458 and DAPT, suppressed Abeta production from CTF1−49. Regarding Abeta production from CTF1−48, L-685,458 suppressed it, but DAPT failed to do so. A dominant negative mutant of presenilin 1 suppressed the production of Abeta40 and 42 from both CTFs1−48 and 1−49. These data should shed significant light into the mechanism of Abeta production.', 'citation': {'type': 'PubMed', 'reference': '15491160'}, 'annotations': {'TextLocation': {'Abstract': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:APP), p(HBP:\"APP C-terminally truncated carboxyl-terminal fragments\")\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 195, 'relation': 'isA', 'evidence': 'We previously showed that beta-amyloid precursor protein (APP) is cleaved not only in the middle of the membrane (gamma-cleavage) but also at novel cleavage sites close to the membrane/cytoplasmic boundary (ε-cleavage), releasing APP intracellular domains (AICDs) 49−99 and 50−99. To learn more about the relationship between gamma- and ε-cleavage, C-terminally truncated carboxyl-terminal fragments (CTFs) of APP, especially CTFs1−48 and 1−49 (the postulated products that are generated by ε-cleavage), were transiently expressed in CHO cells. Most importantly, the cells expressing CTF1−49 secreted predominantly amyloid beta-protein (Abeta) 40, while those expressing CTF1−48 secreted preferentially Abeta42. This supports our assumption that ε-cleavage precedes Αbeta production and that preceding ε-cleavage determines the preference for the final Abeta species. The gamma-secretase inhibitors, L-685,458 and DAPT, suppressed Abeta production from CTF1−49. Regarding Abeta production from CTF1−48, L-685,458 suppressed it, but DAPT failed to do so. A dominant negative mutant of presenilin 1 suppressed the production of Abeta40 and 42 from both CTFs1−48 and 1−49. These data should shed significant light into the mechanism of Abeta production.', 'citation': {'type': 'PubMed', 'reference': '15491160'}, 'annotations': {'TextLocation': {'Abstract': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"amyloid-beta\"), path(MESHD:\"Diabetes Mellitus, Type 2\")\n",
      "WARNING:root:  with edge data {'line': 14033, 'relation': 'biomarkerFor', 'evidence': 'In conclusion, the level of Abeta autoantibody is dramatically elevated in patient serum of T2DM, and, as such, might be used as a possible biomarker for T2DM.', 'citation': {'type': 'PubMed', 'reference': '20061608'}, 'annotations': {'Subgraph': {'Amyloidogenic subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"amyloid-beta\"), p(HGNC:HSPA5)\n",
      "WARNING:root:  with edge data {'line': 25275, 'relation': 'causesNoChange', 'evidence': 'C/EBP homologous protein (CHOP), a pro-apoptotic ER stress protein, was expressed at high levels but glucose-regulated protein 78 (GRP78), an anti-apoptotic ER stress protein with chaperone activity, was only slightly affected by treatment with beta-amyloid.', 'citation': {'type': 'PubMed', 'name': 'Biol Res. 2012;45(4):403-10', 'reference': '23558999'}, 'annotations': {'Subgraph': {'Amyloidogenic subgraph': True, 'Response DNA damage': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"amyloid-beta polypeptide 42\"), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'line': 153, 'relation': 'isA', 'evidence': 'The statements inside this citation is included to connect two entity types or triples, which will exist as islands/subnetworks in the big model.', 'citation': {'type': 'Other', 'name': 'Connectors', 'reference': '123'}}\n",
      "WARNING:root:No converter found for complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:PSEN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:PSEN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:NCSTN)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:NCSTN)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:APH1A)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:PSEN2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:PSEN2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:PSENEN)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:APH1B)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(a(CHEBI:\"amyloid-beta\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(a(CHEBI:\"amyloid-beta\"))), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for path(MESHD:\"Alzheimer Disease\"), p(HGNC:IL1B)\n",
      "WARNING:root:  with edge data {'line': 22417, 'relation': 'causesNoChange', 'evidence': 'Sera from patients with Alzheimer disease and non-demented elderly subjects caused an increase in IL-2 and a decrease in IL-10 production by PBMC from middle-aged control subjects but did not affect IL-1beta, IL-6, and TNFalpha secretion, indicating alterations of the immune system related to aging.', 'citation': {'type': 'PubMed', 'name': 'Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):156-60', 'reference': '12218646'}, 'annotations': {'Subgraph': {'Interleukin signaling subgraph': True}, 'Disease': {\"Alzheimer's disease\": True}, 'MeSHAnatomy': {'Serum': True}, 'Species': {'9606': True}}}\n",
      "WARNING:root:No converter found for path(MESHD:\"Alzheimer Disease\"), p(HGNC:IL6)\n",
      "WARNING:root:  with edge data {'line': 22418, 'relation': 'causesNoChange', 'evidence': 'Sera from patients with Alzheimer disease and non-demented elderly subjects caused an increase in IL-2 and a decrease in IL-10 production by PBMC from middle-aged control subjects but did not affect IL-1beta, IL-6, and TNFalpha secretion, indicating alterations of the immune system related to aging.', 'citation': {'type': 'PubMed', 'name': 'Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):156-60', 'reference': '12218646'}, 'annotations': {'Subgraph': {'Interleukin signaling subgraph': True}, 'Disease': {\"Alzheimer's disease\": True}, 'MeSHAnatomy': {'Serum': True}, 'Species': {'9606': True}}}\n",
      "WARNING:root:No converter found for path(MESHD:\"Alzheimer Disease\"), p(HGNC:TNF)\n",
      "WARNING:root:  with edge data {'line': 22420, 'relation': 'causesNoChange', 'evidence': 'Sera from patients with Alzheimer disease and non-demented elderly subjects caused an increase in IL-2 and a decrease in IL-10 production by PBMC from middle-aged control subjects but did not affect IL-1beta, IL-6, and TNFalpha secretion, indicating alterations of the immune system related to aging.', 'citation': {'type': 'PubMed', 'name': 'Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):156-60', 'reference': '12218646'}, 'annotations': {'Subgraph': {'Tumor necrosis factor subgraph': True}, 'Disease': {\"Alzheimer's disease\": True}, 'MeSHAnatomy': {'Serum': True}, 'Species': {'9606': True}}}\n",
      "WARNING:root:No converter found for path(MESHD:\"Alzheimer Disease\"), path(MESHD:Dementia)\n",
      "WARNING:root:  with edge data {'line': 20150, 'relation': 'isA', 'evidence': \"Alzheimer's disease (AD) is the most prevalent type of dementia.\", 'citation': {'type': 'PubMed', 'name': 'Curr Alzheimer Res. 2012 Oct;9(8):982-9', 'reference': '21875409'}, 'annotations': {'Subgraph': {'Matrix metalloproteinase subgraph': True}, 'Disease': {\"Alzheimer's disease\": True, 'dementia': True}}}\n",
      "WARNING:root:No converter found for path(MESHD:\"Alzheimer Disease\"), a(CHEBI:glutathione)\n",
      "WARNING:root:  with edge data {'line': 19997, 'relation': 'causesNoChange', 'evidence': 'The blood levels of catalase but not superoxide dismutase and glutathione were significantly decreased in the patients with severe AD when compared to controls (p < .01),', 'citation': {'type': 'PubMed', 'reference': '12094909'}, 'annotations': {'MeSHAnatomy': {'Blood': True}, 'Subgraph': {'Glutathione reductase subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for path(MESHD:\"Alzheimer Disease\"), p(HGNC:SOD1)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 19998, 'relation': 'causesNoChange', 'evidence': 'The blood levels of catalase but not superoxide dismutase and glutathione were significantly decreased in the patients with severe AD when compared to controls (p < .01),', 'citation': {'type': 'PubMed', 'reference': '12094909'}, 'annotations': {'MeSHAnatomy': {'Blood': True}, 'Subgraph': {'Glutathione reductase subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for path(MESHD:\"Alzheimer Disease\"), a(CHEBI:serotonin)\n",
      "WARNING:root:  with edge data {'line': 20157, 'relation': 'causesNoChange', 'evidence': 'The APP ratio was slightly but not significantly decreased in AD patients, whereas CD40L and serotonin were unchanged.', 'citation': {'type': 'PubMed', 'name': 'Curr Alzheimer Res. 2012 Oct;9(8):982-9', 'reference': '21875409'}, 'annotations': {'Subgraph': {'T cells signaling': True}}}\n",
      "WARNING:root:No converter found for path(MESHD:\"Alzheimer Disease\"), p(HGNC:CD40LG)\n",
      "WARNING:root:  with edge data {'line': 20158, 'relation': 'causesNoChange', 'evidence': 'The APP ratio was slightly but not significantly decreased in AD patients, whereas CD40L and serotonin were unchanged.', 'citation': {'type': 'PubMed', 'name': 'Curr Alzheimer Res. 2012 Oct;9(8):982-9', 'reference': '21875409'}, 'annotations': {'Subgraph': {'T cells signaling': True}}}\n",
      "WARNING:root:No converter found for path(MESHD:\"Alzheimer Disease\"), p(HGNC:PLAUR)\n",
      "WARNING:root:  with edge data {'line': 25940, 'relation': 'causesNoChange', 'evidence': 'Increased uPAR expression was not demonstrated in AD cerebellum.', 'citation': {'type': 'PubMed', 'name': 'Brain Res. 2002 Feb 1;926(1-2):69-79', 'reference': '11814408'}, 'annotations': {'Subgraph': {'Plasminogen activator subgraph': True}, 'Disease': {\"Alzheimer's disease\": True}, 'MeSHAnatomy': {'Cerebellum': True}}}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"iron(2+)\"), p(HGNC:APP, frag(\"672_713\"))), products(a(CHEBI:\"hydrogen peroxide\"))), a(CHEBI:\"iron(2+)\")\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"iron(2+)\"), p(HGNC:APP, frag(\"672_713\"))), products(a(CHEBI:\"hydrogen peroxide\"))), a(CHEBI:\"hydrogen peroxide\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"iron(2+)\"), p(HGNC:APP, frag(\"672_713\"))), products(a(CHEBI:\"hydrogen peroxide\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for a(CHEBI:\"hydrogen peroxide\"), a(CHEBI:\"reactive oxygen species\")\n",
      "WARNING:root:  with edge data {'line': 18789, 'relation': 'isA', 'evidence': 'Hydrogen peroxide (H2O2), one of the main reactive oxygen species, is converted into the highly toxic Â·OH radical in the presence of redox-active transition metals, which then oxidises nucleic acids, lipids and proteins, leading to neurodegeneration and cell death.', 'citation': {'type': 'PubMed', 'reference': '23653222'}, 'annotations': {'MeSHDisease': {'Neurodegenerative Diseases': True}, 'Subgraph': {'Hydrogen peroxide subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"copper(1+)\"), p(HGNC:APP, frag(\"672_713\"))), products(a(CHEBI:\"hydrogen peroxide\"))), a(CHEBI:\"copper(1+)\")\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"copper(1+)\"), p(HGNC:APP, frag(\"672_713\"))), products(a(CHEBI:\"hydrogen peroxide\"))), a(CHEBI:\"hydrogen peroxide\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"copper(1+)\"), p(HGNC:APP, frag(\"672_713\"))), products(a(CHEBI:\"hydrogen peroxide\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"nitric oxide\"), a(CHEBI:superoxide)), products(a(CHEBI:peroxynitrate))), a(CHEBI:\"nitric oxide\")\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"nitric oxide\"), a(CHEBI:superoxide)), products(a(CHEBI:peroxynitrate))), a(CHEBI:superoxide)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"nitric oxide\"), a(CHEBI:superoxide)), products(a(CHEBI:peroxynitrate))), a(CHEBI:peroxynitrate)\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for path(MESHD:\"Neurogenic Inflammation\"), bp(GOBP:\"inflammatory response\")\n",
      "WARNING:root:  with edge data {'line': 7570, 'relation': 'isA', 'evidence': \"Neuroinflammation contributes to the pathogenesis of sporadic Alzheimer's disease (AD)\", 'citation': {'type': 'PubMed', 'name': 'Int J Mol Epidemiol Genet. 2012;3(1):39-47. Epub 2012 Feb 23.', 'reference': '22493750'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Subgraph': {'Inflammatory response subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for bp(GOBP:\"neuron apoptotic process\"), bp(GOBP:\"apoptotic process\")\n",
      "WARNING:root:  with edge data {'line': 747, 'relation': 'isA', 'evidence': 'The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1Abeta.', 'citation': {'type': 'PubMed', 'reference': '15232608'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Subgraph': {'Amyloidogenic subgraph': True, 'Interleukin signaling subgraph': True}, 'Confidence': {'Very High': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:TNF), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 1829, 'relation': 'biomarkerFor', 'evidence': 'A panel of five markers (CCL5, CSF1, ICAM1, IL8, TNF) with detectable expression levels in all individuals differed between AD patients', 'citation': {'type': 'PubMed', 'name': 'Clin Chem Lab Med. 2011 Sep 23. [Epub ahead of print]', 'reference': '21942811'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Confidence': {'Very High': True}, 'Subgraph': {'Tumor necrosis factor subgraph': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:IL1B), r(HGNC:BACE1)\n",
      "WARNING:root:  with edge data {'line': 31076, 'relation': 'causesNoChange', 'evidence': 'we unexpectedly found that IL-1beta significantly enhanced alpha-cleavage, indicated by increases in sAPPalpha and C83, but reduced beta-cleavage, indicated by decreases in sAPPbeta and Abeta40/42, in human neuroblastoma SK-N-SH cells. IL-1beta did not significantly alter the mRNA levels of BACE1, ADAM-9, and ADAM-10, but up-regulated that of TACE by threefold.', 'citation': {'type': 'PubMed', 'name': 'J Neurochem2008', 'reference': '18021299'}, 'annotations': {'Subgraph': {'Interleukin signaling subgraph': True, 'Beta secretase subgraph': True, 'ADAM Metallopeptidase subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:IL1B), r(HGNC:ADAM10)\n",
      "WARNING:root:  with edge data {'line': 31074, 'relation': 'causesNoChange', 'evidence': 'we unexpectedly found that IL-1beta significantly enhanced alpha-cleavage, indicated by increases in sAPPalpha and C83, but reduced beta-cleavage, indicated by decreases in sAPPbeta and Abeta40/42, in human neuroblastoma SK-N-SH cells. IL-1beta did not significantly alter the mRNA levels of BACE1, ADAM-9, and ADAM-10, but up-regulated that of TACE by threefold.', 'citation': {'type': 'PubMed', 'name': 'J Neurochem2008', 'reference': '18021299'}, 'annotations': {'Subgraph': {'Interleukin signaling subgraph': True, 'Beta secretase subgraph': True, 'ADAM Metallopeptidase subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:MAPT), path(MESHD:\"Alzheimer Disease\")\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 5197, 'relation': 'biomarkerFor', 'evidence': 'Our findings support the notion that CSF tau and Abeta(1-42) may be useful biomarkers in the early identification of AD in MCI subjects.', 'citation': {'type': 'PubMed', 'name': 'Mol Psychiatry. 2004 Jul;9(7):705-10', 'reference': '14699432'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'MeSHAnatomy': {'Cerebrospinal Fluid': True}, 'Confidence': {'High': True}, 'Subgraph': {'Tau protein subgraph': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:MAPT), a(CHEBI:\"Heparin binding peptide\")\n",
      "WARNING:root:  with edge data {'line': 66649, 'relation': 'isA', 'evidence': 'Binding to HSPGs requires a heparin/heparan sulfate-binding domain consisting of a stretch of positively charged lysines or arginines on the ligand. Prion protein, beta-amyloid, tau, and alpha-synuclein all have putative heparin-binding domains(25, 44Ã¢â‚¬â€œ46).', 'citation': {'type': 'PubMed', 'name': 'Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47.', 'reference': '23898162'}, 'annotations': {'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:MAPT), path(MESHD:\"Neurodegenerative Diseases\")\n",
      "WARNING:root:  with edge data {'line': 69198, 'relation': 'biomarkerFor', 'evidence': 'PP2A dysfunction has been linked to tau hyperphosphorylation, amyloidogenesis and synaptic deficits that are pathological hallmarks of this neurodegenerative disorder.', 'citation': {'type': 'PubMed', 'reference': '24653673'}}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:CDK5R1)), products(p(HBP:\"CDK5R1 p25\"))), p(HGNC:CDK5R1)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:CDK5R1)), products(p(HBP:\"CDK5R1 p25\"))), p(HBP:\"CDK5R1 p25\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for p(HGNC:CDK5R1), a(CHEBI:\"EC 3.4.22.56 (caspase-3) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 28255, 'relation': 'isA', 'evidence': 'XIAP expression in motor neurons significantly slows disease progression, whereas p35, a broad caspase inhibitory protein, does not. However, p35, which potently inhibits capase-3, does not slow disease progression in mouse ALS. There are two explanations for this apparent discrepancy. Since caspase-9 remains active in the presence of p35, procaspase-3 may be continuously processed into active caspase-3, finally overriding inhibition by p35. Alternatively, caspase-9 may utilize a substrate other than caspase-3, leading to caspase-3-independent cell death', 'citation': {'type': 'PubMed', 'name': 'EMBO J. 2003 Dec 15;22(24):6665-74', 'reference': '14657037'}, 'annotations': {'Subgraph': {'Caspase subgraph': True, 'XIAP subgraph': True, 'Electron transport chain': True}, 'Species': {'10090': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:CDK5R1), path(MESHD:\"Amyotrophic Lateral Sclerosis\")\n",
      "WARNING:root:  with edge data {'line': 28256, 'relation': 'causesNoChange', 'evidence': 'XIAP expression in motor neurons significantly slows disease progression, whereas p35, a broad caspase inhibitory protein, does not. However, p35, which potently inhibits capase-3, does not slow disease progression in mouse ALS. There are two explanations for this apparent discrepancy. Since caspase-9 remains active in the presence of p35, procaspase-3 may be continuously processed into active caspase-3, finally overriding inhibition by p35. Alternatively, caspase-9 may utilize a substrate other than caspase-3, leading to caspase-3-independent cell death', 'citation': {'type': 'PubMed', 'name': 'EMBO J. 2003 Dec 15;22(24):6665-74', 'reference': '14657037'}, 'annotations': {'Subgraph': {'Caspase subgraph': True, 'XIAP subgraph': True, 'Electron transport chain': True}, 'Species': {'10090': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:CDK5R1), p(MGI:Casp9)\n",
      "WARNING:root:  with edge data {'line': 28257, 'relation': 'causesNoChange', 'evidence': 'XIAP expression in motor neurons significantly slows disease progression, whereas p35, a broad caspase inhibitory protein, does not. However, p35, which potently inhibits capase-3, does not slow disease progression in mouse ALS. There are two explanations for this apparent discrepancy. Since caspase-9 remains active in the presence of p35, procaspase-3 may be continuously processed into active caspase-3, finally overriding inhibition by p35. Alternatively, caspase-9 may utilize a substrate other than caspase-3, leading to caspase-3-independent cell death', 'citation': {'type': 'PubMed', 'name': 'EMBO J. 2003 Dec 15;22(24):6665-74', 'reference': '14657037'}, 'annotations': {'Subgraph': {'Caspase subgraph': True, 'XIAP subgraph': True, 'Electron transport chain': True}, 'Species': {'10090': True}}, 'object': {'modifier': 'Activity'}}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN10)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN5)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN9)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN11)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN7)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN13)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN6)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN15)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN14)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN12)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"CAPN Family\"), p(HGNC:CAPN8)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:CDK5), bp(GOBP:\"cell cycle\")\n",
      "WARNING:root:  with edge data {'line': 10179, 'relation': 'causesNoChange', 'evidence': 'Initially, the expression of p35 was believed to be restricted to the central nervous system, the lens (22), and recently in developing muscle, where it forms a p35/CDK5 active complex that regulates the expression of the acetylcholine receptor gene (23). Despite its name CDK5 does not affect the cell division cycle; it is expressed postmitotically, and its function is related to cytoskeletal dynamics, cell migration, cell differentiation, and exocytosis (14) instead of cellular proliferation. Recently, Pho-85, a yeast ortholog of CDK5, was shown to be involved in metabolic control by regulating different steps of glycogen and phosphate metabolism (13). Expression of CDK5 in insulin-producing cells is not surprising because widespread expression of this kinase has been described. CDK5 expression in beta-cells has also been reported (24).', 'citation': {'type': 'PubMed', 'reference': '14976144'}, 'annotations': {'Subgraph': {'Cyclin-CDK subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:GSK3B), complex(p(HGNC:GSK3B), p(HGNC:PPP2CA))\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 11086, 'relation': 'isA', 'evidence': 'In SHSY5Y cells, a human neuroblastoma cell line, as well as in primary cultu res of rat cortical neurons insulin administration leads to tau hyperphosphorylation (111-113]. In contrast, insulin and IGF- 1 administration in NT2N cells, cultured human neurons, decreases tau phosphorylation [114]. In primary cortical neuron cultures, M esk e et a/ . (115J found that insulin treatment causes a regulatory interaction between PP2A and GSK-3. Inhibition of Pl3-kinase leads to activat ion of GSK-3and PP2A. Enzyme activity of both enzymes al ways changed in the same direction. This balÂ\\xad anced response seemed to induce a steady state in tau phosÂ\\xad phorylation at GSK-3/PP2A-dependent sites (115]. Thus, on ly a dysbalance of insulin/IGF-1 regulated tau kinases and phosphatases might lead to tau hyperphosphorylation, partially explaining the different resu lts obtained under different conditions.', 'citation': {'type': 'PubMed', 'reference': '19519303'}, 'annotations': {'Subgraph': {'Phosphatidylinositol 3 subgraph': True, 'GSK3 subgraph': True}, 'Confidence': {'High': True}}, 'subject': {'modifier': 'Activity'}}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"amyloid-beta\"), p(HGNC:CASP8), p(HGNC:FADD)), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"amyloid-beta\"), p(HGNC:CASP8), p(HGNC:FADD)), p(HGNC:CASP8)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"amyloid-beta\"), p(HGNC:CASP8), p(HGNC:FADD)), p(HGNC:FADD)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:SNCA), a(CHEBI:\"Heparin binding peptide\")\n",
      "WARNING:root:  with edge data {'line': 66650, 'relation': 'isA', 'evidence': 'Binding to HSPGs requires a heparin/heparan sulfate-binding domain consisting of a stretch of positively charged lysines or arginines on the ligand. Prion protein, beta-amyloid, tau, and alpha-synuclein all have putative heparin-binding domains(25, 44Ã¢â‚¬â€œ46).', 'citation': {'type': 'PubMed', 'name': 'Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47.', 'reference': '23898162'}, 'annotations': {'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APOE), p(HGNC:CTSD, var(\"p.Ala224Val\"))), p(HGNC:APOE)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APOE), p(HGNC:CTSD, var(\"p.Ala224Val\"))), p(HGNC:CTSD)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:CHIT1), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 1299, 'relation': 'biomarkerFor', 'evidence': 'As a single marker, chitinase activity was most powerful for distinguishing patients with AD from no dementia patients with an accuracy of 85.8% using a single threshold', 'citation': {'type': 'PubMed', 'name': 'Neurology. 2012 Feb 8. [Epub ahead of print]', 'reference': '22323746'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Confidence': {'Very High': True}, 'Subgraph': {'Innate immune system subgraph': True}}, 'subject': {'modifier': 'Activity'}}\n",
      "WARNING:root:No converter found for p(SFAM:\"MAPK Erk1/2 Family\"), p(HGNC:MAPK11)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"MAPK Erk1/2 Family\"), p(HGNC:MAPK12)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"MAPK Erk1/2 Family\"), p(HGNC:MAPK13)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"MAPK Erk1/2 Family\"), p(HGNC:MAPK14)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"MAPK Erk1/2 Family\"), p(HGNC:MAPK1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"MAPK Erk1/2 Family\"), p(HGNC:MAPK3)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"Chemokine Receptor Family\"), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 1735, 'relation': 'biomarkerFor', 'evidence': \"Some studies have linked the presence of chemokines to the early stages of Alzheimer's disease (AD). Then, the identification of these mediators may contribute to diagnosis. Our objective was to evaluate the levels of beta-amyloid (BA), tau, phospho-tau (p-tau) and chemokines (CCL2, CXCL8 and CXCL10) in the cerebrospinal fluid (CSF) of patients with AD and healthy controls. The correlation of these markers with clinical parameters was also evaluated. The levels of p-tau were higher in AD compared to controls, while the tau/p-tau ratio was decreased. The expression of CCL2 was increased in AD. A positive correlation was observed between BA levels and all chemokines studied, and between CCL2 and p-tau levels. Our results suggest that levels of CCL2 in CSF are involved in the pathogenesis of AD and it may be an additional useful biomarker for monitoring disease progression.\", 'citation': {'type': 'PubMed', 'name': 'Arq Neuropsiquiatr. 2011 Jun;69(3):455-9', 'reference': '21755121'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Confidence': {'Very High': True}, 'Subgraph': {'Chemokine signaling subgraph': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:CCL2), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 1747, 'relation': 'biomarkerFor', 'evidence': \"Some studies have linked the presence of chemokines to the early stages of Alzheimer's disease (AD). Then, the identification of these mediators may contribute to diagnosis. Our objective was to evaluate the levels of beta-amyloid (BA), tau, phospho-tau (p-tau) and chemokines (CCL2, CXCL8 and CXCL10) in the cerebrospinal fluid (CSF) of patients with AD and healthy controls. The correlation of these markers with clinical parameters was also evaluated. The levels of p-tau were higher in AD compared to controls, while the tau/p-tau ratio was decreased. The expression of CCL2 was increased in AD. A positive correlation was observed between BA levels and all chemokines studied, and between CCL2 and p-tau levels. Our results suggest that levels of CCL2 in CSF are involved in the pathogenesis of AD and it may be an additional useful biomarker for monitoring disease progression.\", 'citation': {'type': 'PubMed', 'name': 'Arq Neuropsiquiatr. 2011 Jun;69(3):455-9', 'reference': '21755121'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Subgraph': {'Amyloidogenic subgraph': True, 'Chemokine signaling subgraph': True, 'Interleukin signaling subgraph': True}, 'Confidence': {'Very High': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:CXCL8), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 1827, 'relation': 'biomarkerFor', 'evidence': 'A panel of five markers (CCL5, CSF1, ICAM1, IL8, TNF) with detectable expression levels in all individuals differed between AD patients', 'citation': {'type': 'PubMed', 'name': 'Clin Chem Lab Med. 2011 Sep 23. [Epub ahead of print]', 'reference': '21942811'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Confidence': {'Very High': True}, 'Subgraph': {'Interleukin signaling subgraph': True}}}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP), p(HGNC:CTSD)), products(a(CHEBI:\"amyloid-beta\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP), p(HGNC:CTSD)), products(a(CHEBI:\"amyloid-beta\"))), p(HGNC:CTSD)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP), p(HGNC:CTSD)), products(a(CHEBI:\"amyloid-beta\"))), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for p(HGNC:CCL5), path(MESHD:\"Alzheimer Disease\")\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 1819, 'relation': 'biomarkerFor', 'evidence': 'A panel of five markers (CCL5, CSF1, ICAM1, IL8, TNF) with detectable expression levels in all individuals differed between AD patients', 'citation': {'type': 'PubMed', 'name': 'Clin Chem Lab Med. 2011 Sep 23. [Epub ahead of print]', 'reference': '21942811'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Confidence': {'Very High': True}, 'Subgraph': {'Chemokine signaling subgraph': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:CSF1), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 1822, 'relation': 'biomarkerFor', 'evidence': 'A panel of five markers (CCL5, CSF1, ICAM1, IL8, TNF) with detectable expression levels in all individuals differed between AD patients', 'citation': {'type': 'PubMed', 'name': 'Clin Chem Lab Med. 2011 Sep 23. [Epub ahead of print]', 'reference': '21942811'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Confidence': {'Very High': True}, 'Subgraph': {'Inflammatory response subgraph': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:ICAM1), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 1825, 'relation': 'biomarkerFor', 'evidence': 'A panel of five markers (CCL5, CSF1, ICAM1, IL8, TNF) with detectable expression levels in all individuals differed between AD patients', 'citation': {'type': 'PubMed', 'name': 'Clin Chem Lab Med. 2011 Sep 23. [Epub ahead of print]', 'reference': '21942811'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Confidence': {'Very High': True}, 'Subgraph': {'Low density lipoprotein subgraph': True, 'Cell adhesion subgraph': True, 'Inflammatory response subgraph': True}}}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APBB1), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\")), p(HGNC:APBB1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APBB1), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\")), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for complex(GOCC:\"respiratory chain complex IV\"), p(ECCODE:\"1.9.3.1\")\n",
      "WARNING:root:  with edge data {'line': 2125, 'relation': 'isA', 'evidence': 'The accumulation of APP across mitochondrial import channels inhibited the entry of nuclear-encoded cytochrome c-oxidase subunits IV and Vb proteins and was associated with decreased cytochrome oxidase and increased free radical production', 'citation': {'type': 'PubMed', 'reference': '22523685'}, 'annotations': {'CellStructure': {'Mitochondria': True}, 'Disease': {\"Alzheimer's disease\": True}, 'Subgraph': {'Amyloidogenic subgraph': True, 'Reactive oxygen species subgraph': True, 'Electron transport chain': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:PSEN1)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:PSEN1)), p(HGNC:PSEN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:KAT5), p(INTERPRO:\"Histone acetyltransferase domain, MYST-type\")\n",
      "WARNING:root:  with edge data {'line': 45191, 'relation': 'isA', 'evidence': 'Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3ÃƒÅ¸, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes', 'citation': {'type': 'PubMed', 'name': 'BMB Rep. 2010 Oct;43(10):656-63.', 'reference': '21034527'}, 'annotations': {'Published': {'CDR story': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APLP1), p(HGNC:APLP2), p(HGNC:APP)), p(HGNC:APLP1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APLP1), p(HGNC:APLP2), p(HGNC:APP)), p(HGNC:APLP2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APLP1), p(HGNC:APLP2), p(HGNC:APP)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:PSEN1), p(HGNC:PSEN2)), p(HGNC:PSEN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:PSEN1), p(HGNC:PSEN2)), p(HGNC:PSEN2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(GFAM:\"MTOR complex 1\"), p(HGNC:LRP1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"MTOR complex 1\"), p(HGNC:LRP2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"MTOR complex 1\"), p(HGNC:LRP3)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"MTOR complex 1\"), p(HGNC:LRP4)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"MTOR complex 1\"), p(HGNC:LRP5)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"MTOR complex 1\"), p(HGNC:LRP6)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"MTOR complex 1\"), p(HGNC:LRP8)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"MTOR complex 1\"), p(HGNC:LRP10)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"MTOR complex 1\"), p(HGNC:LRP11)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:LRP1), p(HGNC:LRP10), p(HGNC:LRP11), p(HGNC:LRP2), p(HGNC:LRP3), p(HGNC:LRP4), p(HGNC:LRP5), p(HGNC:LRP6), p(HGNC:LRP8)), p(HGNC:LRP1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:LRP1), p(HGNC:LRP10), p(HGNC:LRP11), p(HGNC:LRP2), p(HGNC:LRP3), p(HGNC:LRP4), p(HGNC:LRP5), p(HGNC:LRP6), p(HGNC:LRP8)), p(HGNC:LRP10)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:LRP1), p(HGNC:LRP10), p(HGNC:LRP11), p(HGNC:LRP2), p(HGNC:LRP3), p(HGNC:LRP4), p(HGNC:LRP5), p(HGNC:LRP6), p(HGNC:LRP8)), p(HGNC:LRP11)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:LRP1), p(HGNC:LRP10), p(HGNC:LRP11), p(HGNC:LRP2), p(HGNC:LRP3), p(HGNC:LRP4), p(HGNC:LRP5), p(HGNC:LRP6), p(HGNC:LRP8)), p(HGNC:LRP2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:LRP1), p(HGNC:LRP10), p(HGNC:LRP11), p(HGNC:LRP2), p(HGNC:LRP3), p(HGNC:LRP4), p(HGNC:LRP5), p(HGNC:LRP6), p(HGNC:LRP8)), p(HGNC:LRP3)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:LRP1), p(HGNC:LRP10), p(HGNC:LRP11), p(HGNC:LRP2), p(HGNC:LRP3), p(HGNC:LRP4), p(HGNC:LRP5), p(HGNC:LRP6), p(HGNC:LRP8)), p(HGNC:LRP4)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:LRP1), p(HGNC:LRP10), p(HGNC:LRP11), p(HGNC:LRP2), p(HGNC:LRP3), p(HGNC:LRP4), p(HGNC:LRP5), p(HGNC:LRP6), p(HGNC:LRP8)), p(HGNC:LRP5)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:LRP1), p(HGNC:LRP10), p(HGNC:LRP11), p(HGNC:LRP2), p(HGNC:LRP3), p(HGNC:LRP4), p(HGNC:LRP5), p(HGNC:LRP6), p(HGNC:LRP8)), p(HGNC:LRP6)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:LRP1), p(HGNC:LRP10), p(HGNC:LRP11), p(HGNC:LRP2), p(HGNC:LRP3), p(HGNC:LRP4), p(HGNC:LRP5), p(HGNC:LRP6), p(HGNC:LRP8)), p(HGNC:LRP8)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:No converter found for composite(p(HBP:\"CDK5R1 p25\"), p(HGNC:CCNB1), p(HGNC:CDK1), p(HGNC:CDK4), p(HGNC:CDK9), p(HGNC:CDKN2A), p(HGNC:MKI67)), p(HBP:\"CDK5R1 p25\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HBP:\"CDK5R1 p25\"), p(HGNC:CCNB1), p(HGNC:CDK1), p(HGNC:CDK4), p(HGNC:CDK9), p(HGNC:CDKN2A), p(HGNC:MKI67)), p(HGNC:CCNB1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HBP:\"CDK5R1 p25\"), p(HGNC:CCNB1), p(HGNC:CDK1), p(HGNC:CDK4), p(HGNC:CDK9), p(HGNC:CDKN2A), p(HGNC:MKI67)), p(HGNC:CDK1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HBP:\"CDK5R1 p25\"), p(HGNC:CCNB1), p(HGNC:CDK1), p(HGNC:CDK4), p(HGNC:CDK9), p(HGNC:CDKN2A), p(HGNC:MKI67)), p(HGNC:CDK4)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HBP:\"CDK5R1 p25\"), p(HGNC:CCNB1), p(HGNC:CDK1), p(HGNC:CDK4), p(HGNC:CDK9), p(HGNC:CDKN2A), p(HGNC:MKI67)), p(HGNC:CDK9)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HBP:\"CDK5R1 p25\"), p(HGNC:CCNB1), p(HGNC:CDK1), p(HGNC:CDK4), p(HGNC:CDK9), p(HGNC:CDKN2A), p(HGNC:MKI67)), p(HGNC:CDKN2A)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HBP:\"CDK5R1 p25\"), p(HGNC:CCNB1), p(HGNC:CDK1), p(HGNC:CDK4), p(HGNC:CDK9), p(HGNC:CDKN2A), p(HGNC:MKI67)), p(HGNC:MKI67)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:GRIN2B), p(HGNC:GRIN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:GRIN2B), p(HGNC:GRIN2A)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:GRIN2B), p(HGNC:GRIN2C)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:GRIN2B), p(HGNC:GRIN2D)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:GRIN2B), p(HGNC:GRIN3A)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:GRIN2B), p(HGNC:GRIN3B)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:WASF1), p(HGNC:WASF2), p(HGNC:WASF2)), p(HGNC:WASF1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:WASF1), p(HGNC:WASF2), p(HGNC:WASF2)), p(HGNC:WASF2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"L-glutamate(1-)\"), a(CHEBI:\"amyloid-beta\")), a(CHEBI:\"L-glutamate(1-)\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"L-glutamate(1-)\"), a(CHEBI:\"amyloid-beta\")), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:SPTLC3), bp(GOBP:\"ceramide biosynthetic process\")\n",
      "WARNING:root:  with edge data {'line': 12360, 'relation': 'rateLimitingStepOf', 'evidence': 'Increased brain ceramide levels have been associated with sporadic AD, and are a suggested risk factor. Serine palmitoyltransferase (SPT) is the first rate-limiting enzyme in the de novo ceramide synthesis. However, the regulation of SPT is not yet understood. Evidence suggests that it may be posttranscriptionally regulated. Therefore, we investigated the role of miRNAs in the regulation of SPT and amyloid beta (Abeta) generation. We show that SPT is upregulated in a subgroup of sporadic AD patient brains. This is further confirmed in mouse model studies of risk factors associated with AD. We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD.', 'citation': {'type': 'PubMed', 'reference': '21994399'}, 'annotations': {'Subgraph': {'Sphingolipid metabolic subgraph': True}, 'Confidence': {'High': True}}, 'subject': {'modifier': 'Activity', 'effect': {'name': 'cat', 'namespace': 'bel'}}}\n",
      "WARNING:root:No converter found for composite(g(HGNC:PSEN1), g(HGNC:PSEN2)), g(HGNC:PSEN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(g(HGNC:PSEN1), g(HGNC:PSEN2)), g(HGNC:PSEN2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APBB1), p(HGNC:APP)), p(HGNC:APBB1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APBB1), p(HGNC:APP)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:PRNP), a(CHEBI:\"Heparin binding peptide\")\n",
      "WARNING:root:  with edge data {'line': 66647, 'relation': 'isA', 'evidence': 'Binding to HSPGs requires a heparin/heparan sulfate-binding domain consisting of a stretch of positively charged lysines or arginines on the ligand. Prion protein, beta-amyloid, tau, and alpha-synuclein all have putative heparin-binding domains(25, 44Ã¢â‚¬â€œ46).', 'citation': {'type': 'PubMed', 'name': 'Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47.', 'reference': '23898162'}, 'annotations': {'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:ganglioside), a(CHEBI:\"ganglioside GM1\")\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(CHEBI:ganglioside), a(CHEBI:\"beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer\")\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(CHEBI:ganglioside), a(CHEBI:\"beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Gal-p-(1->4)-beta-D-Glcp\")\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(CHEBI:ganglioside), a(CHEBI:\"ganglioside GT1b\")\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"sialic acid\")), products(a(CHEBI:\"alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-Glcp\"))), a(CHEBI:\"sialic acid\")\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"sialic acid\")), products(a(CHEBI:\"alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-Glcp\"))), a(CHEBI:\"alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-Glcp\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for p(HGNC:CR1), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 49670, 'relation': 'biomarkerFor', 'evidence': \"The complement component receptor 1 gene (Cr1), which encodes a type-I transmembrane glycoprotein, has recently been identified as one of the most important risk genes for late-onset Alzheimer's disease (LOAD).\", 'citation': {'type': 'PubMed', 'reference': '24794147'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}}}\n",
      "WARNING:root:No converter found for composite(p(HGNC:SRSF5), p(HGNC:TSG101)), p(HGNC:SRSF5)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:SRSF5), p(HGNC:TSG101)), p(HGNC:TSG101)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CHMP6), p(HGNC:VPS4A), p(HGNC:VPS4B)), p(HGNC:CHMP6)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CHMP6), p(HGNC:VPS4A), p(HGNC:VPS4B)), p(HGNC:VPS4A)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CHMP6), p(HGNC:VPS4A), p(HGNC:VPS4B)), p(HGNC:VPS4B)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:SERPINA3), path(MESHD:\"Nerve Degeneration\")\n",
      "WARNING:root:  with edge data {'line': 47562, 'relation': 'biomarkerFor', 'evidence': \" Glial fibrillary acidic protein and antibodies in CSF may be a marker for severe neurodegeneration. CSF concentrations of the oxidative stress markers 3-nitrotyrosine, 8-hydroxy-2'-deoxyguanosine and isoprostanes are increased in AD patients. Serum 24S-OH-cholesterol may be an early whereas glial fibrillary acidic protein autoantibody level may be a late marker for neurodegeneration. To date, serum alpha(1)-Antichymotripsin concentration is the most convincing marker for CNS inflammation. Increased serum homocysteine concentrations have also been consistently reported in AD\", 'citation': {'type': 'PubMed', 'name': 'Neurobiol Aging. 2002 Jul-Aug;23(4):485-508.', 'reference': '12009495'}, 'annotations': {'Subgraph': {'Response to oxidative stress': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for rxn(reactants(complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:APP), p(HGNC:BACE1), p(HGNC:BACE2)), products(a(CHEBI:\"amyloid-beta\"))), complex(SCOMP:\"gamma Secretase Complex\")\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:APP), p(HGNC:BACE1), p(HGNC:BACE2)), products(a(CHEBI:\"amyloid-beta\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:APP), p(HGNC:BACE1), p(HGNC:BACE2)), products(a(CHEBI:\"amyloid-beta\"))), p(HGNC:BACE1)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:APP), p(HGNC:BACE1), p(HGNC:BACE2)), products(a(CHEBI:\"amyloid-beta\"))), p(HGNC:BACE2)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(complex(SCOMP:\"gamma Secretase Complex\"), p(HGNC:APP), p(HGNC:BACE1), p(HGNC:BACE2)), products(a(CHEBI:\"amyloid-beta\"))), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"copper(1+)\"), a(CHEBI:\"iron(2+)\"), p(HGNC:APP, frag(\"672_713\"))), products(a(CHEBI:\"hydrogen peroxide\"), a(CHEBI:hydroxyl))), a(CHEBI:\"copper(1+)\")\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"copper(1+)\"), a(CHEBI:\"iron(2+)\"), p(HGNC:APP, frag(\"672_713\"))), products(a(CHEBI:\"hydrogen peroxide\"), a(CHEBI:hydroxyl))), a(CHEBI:\"iron(2+)\")\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"copper(1+)\"), a(CHEBI:\"iron(2+)\"), p(HGNC:APP, frag(\"672_713\"))), products(a(CHEBI:\"hydrogen peroxide\"), a(CHEBI:hydroxyl))), a(CHEBI:\"hydrogen peroxide\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"copper(1+)\"), a(CHEBI:\"iron(2+)\"), p(HGNC:APP, frag(\"672_713\"))), products(a(CHEBI:\"hydrogen peroxide\"), a(CHEBI:hydroxyl))), a(CHEBI:hydroxyl)\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"copper(1+)\"), a(CHEBI:\"iron(2+)\"), p(HGNC:APP, frag(\"672_713\"))), products(a(CHEBI:\"hydrogen peroxide\"), a(CHEBI:hydroxyl))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\"))), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:ADAM10), p(HGNC:APP)), products(a(HBP:\"sAPP-alpha\"))), p(HGNC:ADAM10)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:ADAM10), p(HGNC:APP)), products(a(HBP:\"sAPP-alpha\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:ADAM10), p(HGNC:APP)), products(a(HBP:\"sAPP-alpha\"))), a(HBP:\"sAPP-alpha\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for p(SFAM:\"MAPK p38 Family\"), p(MGI:Mapk11)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"MAPK p38 Family\"), p(MGI:Mapk12)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"MAPK p38 Family\"), p(MGI:Mapk13)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"MAPK p38 Family\"), p(MGI:Mapk14)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(MESH:D058468), p(GFAM:\"Glutamate ionotropic receptor kainate type subunits\")\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(MESH:D058468), p(GFAM:\"Glutamate ionotropic receptor NMDA type subunits\")\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(MESH:D058468), p(GFAM:\"Glutamate ionotropic receptor AMPA type subunits\")\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CAMK2A), p(HGNC:CAMK2B)), p(HGNC:CAMK2A)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CAMK2A), p(HGNC:CAMK2B)), p(HGNC:CAMK2B)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:CAMK2B), p(HGNC:MAPT)\n",
      "WARNING:root:  with edge data {'line': 41002, 'relation': 'causesNoChange', 'evidence': ' Finally, CaM kinase II is present in neurons but not in glial cells, thus suggesting no role of CaM kinase II in tau phosphorylation of glial cells. These observations, together with previous results of in vitro studies, support the idea that several MAPK/ERK, SAPK/JNK, p38 and CaM kinase II may participate in tau phosphorylation in tauopathies', 'citation': {'type': 'PubMed', 'name': 'J Neural Transm. 2001;108(12):1397-415.', 'reference': '11810404'}, 'annotations': {'Confidence': {'High': True}, 'Subgraph': {'Tau protein subgraph': True}, 'MeSHAnatomy': {'Microglia': True}}}\n",
      "WARNING:root:No converter found for composite(p(HGNC:TGFB1), p(HGNC:TGFB2), p(HGNC:TGFB3)), p(HGNC:TGFB1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:TGFB1), p(HGNC:TGFB2), p(HGNC:TGFB3)), p(HGNC:TGFB2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:TGFB1), p(HGNC:TGFB2), p(HGNC:TGFB3)), p(HGNC:TGFB3)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:C1QBP)), p(HGNC:C1QBP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:C1QBP)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:ITGA2B)), p(HGNC:ITGA2B)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:ITGA2B)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:TNFRSF1A)), p(HGNC:TNFRSF1A)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:TNFRSF1A)), p(HGNC:APP)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(a(CHEBI:\"amyloid-beta\"), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(a(CHEBI:\"amyloid-beta\"), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\"))), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(a(CHEBI:\"amyloid-beta\"), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\"))), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CRK), p(HGNC:PIK3R2), p(HGNC:SIT1)), p(HGNC:CRK)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CRK), p(HGNC:PIK3R2), p(HGNC:SIT1)), p(HGNC:PIK3R2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CRK), p(HGNC:PIK3R2), p(HGNC:SIT1)), p(HGNC:SIT1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:MAPK1), p(HGNC:MAPK8), p(HGNC:PIK3R2), p(HGNC:PIK3R5), p(HGNC:RAC1), p(HGNC:RASGRF1), p(HGNC:RHOA), p(HGNC:SKAP2)), p(HGNC:MAPK1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:MAPK1), p(HGNC:MAPK8), p(HGNC:PIK3R2), p(HGNC:PIK3R5), p(HGNC:RAC1), p(HGNC:RASGRF1), p(HGNC:RHOA), p(HGNC:SKAP2)), p(HGNC:MAPK8)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:MAPK1), p(HGNC:MAPK8), p(HGNC:PIK3R2), p(HGNC:PIK3R5), p(HGNC:RAC1), p(HGNC:RASGRF1), p(HGNC:RHOA), p(HGNC:SKAP2)), p(HGNC:PIK3R2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:MAPK1), p(HGNC:MAPK8), p(HGNC:PIK3R2), p(HGNC:PIK3R5), p(HGNC:RAC1), p(HGNC:RASGRF1), p(HGNC:RHOA), p(HGNC:SKAP2)), p(HGNC:PIK3R5)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:MAPK1), p(HGNC:MAPK8), p(HGNC:PIK3R2), p(HGNC:PIK3R5), p(HGNC:RAC1), p(HGNC:RASGRF1), p(HGNC:RHOA), p(HGNC:SKAP2)), p(HGNC:RAC1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:MAPK1), p(HGNC:MAPK8), p(HGNC:PIK3R2), p(HGNC:PIK3R5), p(HGNC:RAC1), p(HGNC:RASGRF1), p(HGNC:RHOA), p(HGNC:SKAP2)), p(HGNC:RASGRF1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:MAPK1), p(HGNC:MAPK8), p(HGNC:PIK3R2), p(HGNC:PIK3R5), p(HGNC:RAC1), p(HGNC:RASGRF1), p(HGNC:RHOA), p(HGNC:SKAP2)), p(HGNC:RHOA)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:MAPK1), p(HGNC:MAPK8), p(HGNC:PIK3R2), p(HGNC:PIK3R5), p(HGNC:RAC1), p(HGNC:RASGRF1), p(HGNC:RHOA), p(HGNC:SKAP2)), p(HGNC:SKAP2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:GFAP), path(MESHD:\"Nerve Degeneration\")\n",
      "WARNING:root:  with edge data {'line': 47551, 'relation': 'biomarkerFor', 'evidence': \" Glial fibrillary acidic protein and antibodies in CSF may be a marker for severe neurodegeneration. CSF concentrations of the oxidative stress markers 3-nitrotyrosine, 8-hydroxy-2'-deoxyguanosine and isoprostanes are increased in AD patients. Serum 24S-OH-cholesterol may be an early whereas glial fibrillary acidic protein autoantibody level may be a late marker for neurodegeneration. To date, serum alpha(1)-Antichymotripsin concentration is the most convincing marker for CNS inflammation. Increased serum homocysteine concentrations have also been consistently reported in AD\", 'citation': {'type': 'PubMed', 'name': 'Neurobiol Aging. 2002 Jul-Aug;23(4):485-508.', 'reference': '12009495'}, 'annotations': {'Subgraph': {'Chaperone subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CSK), p(HGNC:PSEN1)), p(HGNC:CSK)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CSK), p(HGNC:PSEN1)), p(HGNC:PSEN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IL1A), p(HGNC:IL1B)), p(HGNC:IL1A)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IL1A), p(HGNC:IL1B)), p(HGNC:IL1B)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IFNG), p(HGNC:TNF)), p(HGNC:IFNG)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IFNG), p(HGNC:TNF)), p(HGNC:TNF)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"24-hydroxycholesterol\"), a(CHEBI:cholesterol), a(MESHC:\"27-hydroxycholesterol\")), a(CHEBI:\"24-hydroxycholesterol\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"24-hydroxycholesterol\"), a(CHEBI:cholesterol), a(MESHC:\"27-hydroxycholesterol\")), a(CHEBI:cholesterol)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"24-hydroxycholesterol\"), a(CHEBI:cholesterol), a(MESHC:\"27-hydroxycholesterol\")), a(MESHC:\"27-hydroxycholesterol\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(g(DBSNP:rs3818361), g(DBSNP:rs429358)), g(DBSNP:rs429358)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(g(DBSNP:rs3818361), g(DBSNP:rs429358)), g(HGNC:CR1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(g(HGNC:CLTC), g(HGNC:DNM2), g(HGNC:PICALM)), g(HGNC:CLTC)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(g(HGNC:CLTC), g(HGNC:DNM2), g(HGNC:PICALM)), g(HGNC:DNM2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(g(HGNC:CLTC), g(HGNC:DNM2), g(HGNC:PICALM)), g(HGNC:PICALM)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CASP1), p(HGNC:SCAF11)), p(HGNC:CASP1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CASP1), p(HGNC:SCAF11)), p(HGNC:SCAF11)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:GRIA1), p(HGNC:GRIA2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:GRIA1), p(HGNC:GRIA3)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:GRIA1), p(HGNC:GRIA4)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APBA1), p(HGNC:APBA2), p(HGNC:APBA3), p(HGNC:APP)), p(HGNC:APBA1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APBA1), p(HGNC:APBA2), p(HGNC:APBA3), p(HGNC:APP)), p(HGNC:APBA2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APBA1), p(HGNC:APBA2), p(HGNC:APBA3), p(HGNC:APP)), p(HGNC:APBA3)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APBA1), p(HGNC:APBA2), p(HGNC:APBA3), p(HGNC:APP)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APBA1), p(HGNC:APBA2), p(HGNC:APBA3)), p(HGNC:APBA1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:No converter found for composite(p(HGNC:APBA1), p(HGNC:APBA2), p(HGNC:APBA3)), p(HGNC:APBA2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APBA1), p(HGNC:APBA2), p(HGNC:APBA3)), p(HGNC:APBA3)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:AKT1), bp(MESHPP:\"Insulin Resistance\")\n",
      "WARNING:root:  with edge data {'line': 8760, 'relation': 'biomarkerFor', 'evidence': 'Abnormal phosphorylation of tau and activation of mu-calpain are two key events in the pathology of AD. Importantly, these two events are also related with GCs and IR. We therefore speculate that tau phosphorylation and mu-calpain activation may mediate the GCs-induced IR. Akt phosphorylation at Ser-473 (pAkt) is commonly used as a marker for assessing IR.', 'citation': {'type': 'PubMed', 'reference': '22536436'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Subgraph': {'Akt subgraph': True, 'Insulin signal transduction': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"lithium chloride\"), a(CHEBI:\"EC 2.7.11.26 (tau-protein kinase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 17139, 'relation': 'isA', 'evidence': \"Thus, we addressed this paradoxical condition of AD in rat neurons treated with okadaic acid (OA) which inhibits protein phosphatase-2A (PP2A) and induces tau hyperphosphorylation and cell death. Interestingly, OA also induces phosphorylation of GSK3beta at serine-9 and other substrates including tau, beta-catenin and CRMP2 like in AD brains. In this context, we observed that GSK3beta inhibitors such as lithium chloride and 6-bromoindirubin-3'-monoxime (6-BIO) reversed those phosphorylation events and protected neurons. These data suggest that GSK3beta may still have its kinase activity despite increase of its phosphorylation at serine-9 in AD brains at least in PP2A-compromised conditions and that GSK3beta inhibitors could be a valuable drug candidate in AD.\", 'citation': {'type': 'PubMed', 'reference': '15314261'}, 'annotations': {'Species': {'10116': True}, 'MeSHAnatomy': {'Neurons': True}, 'Disease': {\"Alzheimer's disease\": True}, 'Subgraph': {'Axonal guidance subgraph': True, 'Nerve growth factor subgraph': True, 'Regulation of actin cytoskeleton subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(p(HGNC:APP, frag(\"672_713\")))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(p(HGNC:APP, frag(\"672_713\")))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for p(HGNC:INS), bp(GOBP:\"glucose transport\")\n",
      "WARNING:root:  with edge data {'line': 9397, 'relation': 'causesNoChange', 'evidence': 'Glucose transport within the brain is mostly insulin independent, suggesting that the primary role of brain insulin might be in signal transduction pathways involved in cognitive processes [Schulingkamp et al., 2000]. Indeed, studies have shown that insulin and insulin receptors are abundantly but selectively distributed in brain areas that are important for learning and memory [Schulingkamp et al., 2000], and treatment of both normal healthy individuals and patients with mild AD with insulin has been shown to improve cognition [Watson and Craft, 2004].', 'citation': {'type': 'PubMed', 'reference': '19885299'}, 'annotations': {'Subgraph': {'Insulin signal transduction': True}, 'MeSHAnatomy': {'Brain': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:INS), a(CHEBI:glucose)\n",
      "WARNING:root:  with edge data {'line': 10875, 'relation': 'causesNoChange', 'evidence': 'Clinical tr ials in health y hum ans under hyper insulin emic euglycemic clamp conditions showed a n egative shi ft in transcortica l direct current potentials, indicati ng that circ ulatÂ\\xad ing insulin can rapidly act on brain activity independent from its systemic effects [91 ]. Longitudinal studies revealed th at insulin resistance with persisting hyperi nsu linem i a comes along w ith an elevated risk for disturbed cognition, impa ired memory and A D (10, 92, 93]. In AD patients as well as i n h ealthy subjects hyperinsulinemic eug lycemic clamp studies revea led an i mproving effect of.insu li n on cognitive functio n (94, 95]. Intranasa l app l ication of insu lin in healthy hum ans directly entered th e CSF and improved memory function and cogn it ive capacity especi a lly in women with out in fluencing per i phera l blood gl ucose levels (96-98]. These gender speÂ\\xad cific findings suggest an influence of sex hormon es. Accord Â\\xad ingly, Cl egg el a!. d emonstrated th a t i nsul in sensitiv i ty in ra t brains differ, dependin g on estrogen levels (99].', 'citation': {'type': 'PubMed', 'reference': '19519303'}, 'annotations': {'Subgraph': {'Insulin signal transduction': True}, 'Gender': {'Female': True}, 'MeSHAnatomy': {'Blood': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for path(MESHD:Amyloidosis), a(MESHC:\"Thiobarbituric Acid Reactive Substances\")\n",
      "WARNING:root:  with edge data {'line': 50080, 'relation': 'causesNoChange', 'evidence': 'The hippocampal lipid peroxidation correlated strongly with the increase of LOC positive fiber load, whereas neocortical TBARS levels were unrelated to amyloidosis. These data illustrate for the first time the progression of major AD related neuropathological features other than plaque load in the APPSL mouse model.', 'citation': {'type': 'PubMed', 'name': 'Journal of neuroinflammation; Vol. 11; Iss. 1', 'reference': '24886182'}, 'annotations': {'MeSHDisease': {'Plaque, Amyloid': True, 'Amyloidosis': True}, 'Species': {'10090': True}, 'MeSHAnatomy': {'Hippocampus': True, 'Neocortex': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:rosiglitazone), a(CHEBI:\"PPARgamma agonist\")\n",
      "WARNING:root:  with edge data {'line': 9667, 'relation': 'isA', 'evidence': \"Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPARgamma leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against Abeta neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in beta-catenin and inhibition of GSK-3beta is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPARgamma by a potent ligand leads to beta-catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPARgamma activation in neuroprotection, PPARgamma agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPARgamma activation . A recent report demonstrates that overexpression of PPARgamma in cultured cells leads to a dramatic decrease in the production of Abeta, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing Abeta secretion, PPARgamma protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].\", 'citation': {'type': 'PubMed', 'reference': '19885299'}, 'annotations': {'Subgraph': {'Peroxisome proliferator activated receptor subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:metformin), a(CHEBI:\"amyloid-beta\")\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 9856, 'relation': 'causesNoChange', 'evidence': \"Furthermore, the effect of metformin on Abeta generation is mediated by transcriptional up-regulation of beta-secretase (BACE1), which results in an elevated protein level and increased enzymatic activity. Unlike insulin, metformin exerts no effect on Abeta degradation. In addition, we found that glucose deprivation and various tyrphostins, known inhibitors of insulin-like growth factors/insulin receptor tyrosine kinases, do not modulate the effect of metformin on Abeta. Finally, inhibition of AMP-activated protein kinase (AMPK) by the pharmacological inhibitor Compound C largely suppresses metformin's effect on Abeta generation and BACE1 transcription, suggesting an AMPK-dependent mechanism. Although insulin and metformin display opposing effects on Abeta generation, in combined use, metformin enhances insulin's effect in reducing Abeta levels\", 'citation': {'type': 'PubMed', 'name': 'Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.', 'reference': '19237574'}, 'annotations': {'Subgraph': {'Amyloidogenic subgraph': True, 'Beta secretase subgraph': True, 'Insulin signal transduction': True}, 'Confidence': {'Medium': True}}, 'object': {'modifier': 'Degradation'}}\n",
      "WARNING:root:No converter found for a(CHEBI:metformin), bp(GOBP:\"glucose metabolic process\")\n",
      "WARNING:root:  with edge data {'line': 9985, 'relation': 'causesNoChange', 'evidence': 'Taken together, these results indicate that metformin likely augments Abeta production through mechanisms independent of insulin signaling and glucose metabolism', 'citation': {'type': 'PubMed', 'name': 'Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.', 'reference': '19237574'}, 'annotations': {'Subgraph': {'Insulin signal transduction': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:metformin), p(HGNC:IDE)\n",
      "WARNING:root:  with edge data {'line': 9965, 'relation': 'causesNoChange', 'evidence': 'We next studied the potential effect of metformin on the levels of 2 enzymes known to degrade Abeta, neprilysin and insulin-degrading enzyme (IDE). Metformin had no effect on both enzymes, including protein levels and their activities (Fig. S2 A and B). Moreover, metformin had no effect on Abeta degradation as measured by pulseâ€“chase assay (Fig. S2C). We also found that the increased Abeta production caused by metformin was not due to increased APP expression, because the total APP level was unaltered (Fig. 1D).', 'citation': {'type': 'PubMed', 'name': 'Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.', 'reference': '19237574'}, 'annotations': {'Subgraph': {'Insulin signal transduction': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:metformin), p(HGNC:MME)\n",
      "WARNING:root:  with edge data {'line': 9966, 'relation': 'causesNoChange', 'evidence': 'We next studied the potential effect of metformin on the levels of 2 enzymes known to degrade Abeta, neprilysin and insulin-degrading enzyme (IDE). Metformin had no effect on both enzymes, including protein levels and their activities (Fig. S2 A and B). Moreover, metformin had no effect on Abeta degradation as measured by pulseâ€“chase assay (Fig. S2C). We also found that the increased Abeta production caused by metformin was not due to increased APP expression, because the total APP level was unaltered (Fig. 1D).', 'citation': {'type': 'PubMed', 'name': 'Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.', 'reference': '19237574'}, 'annotations': {'Subgraph': {'Insulin signal transduction': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:metformin), bp(GOBP:\"insulin receptor signaling pathway\")\n",
      "WARNING:root:  with edge data {'line': 9986, 'relation': 'causesNoChange', 'evidence': 'Taken together, these results indicate that metformin likely augments Abeta production through mechanisms independent of insulin signaling and glucose metabolism', 'citation': {'type': 'PubMed', 'name': 'Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.', 'reference': '19237574'}, 'annotations': {'Subgraph': {'Insulin signal transduction': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for p(SFAM:\"PRKAA Family\"), p(HGNC:PRKAA1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"PRKAA Family\"), p(HGNC:PRKAA2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(CHEBI:dorsomorphin), a(CHEBI:\"EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 9859, 'relation': 'isA', 'evidence': \"Furthermore, the effect of metformin on Abeta generation is mediated by transcriptional up-regulation of beta-secretase (BACE1), which results in an elevated protein level and increased enzymatic activity. Unlike insulin, metformin exerts no effect on Abeta degradation. In addition, we found that glucose deprivation and various tyrphostins, known inhibitors of insulin-like growth factors/insulin receptor tyrosine kinases, do not modulate the effect of metformin on Abeta. Finally, inhibition of AMP-activated protein kinase (AMPK) by the pharmacological inhibitor Compound C largely suppresses metformin's effect on Abeta generation and BACE1 transcription, suggesting an AMPK-dependent mechanism. Although insulin and metformin display opposing effects on Abeta generation, in combined use, metformin enhances insulin's effect in reducing Abeta levels\", 'citation': {'type': 'PubMed', 'name': 'Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.', 'reference': '19237574'}, 'annotations': {'Subgraph': {'Amyloidogenic subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:metformin), p(HGNC:INS)), a(CHEBI:metformin)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:metformin), p(HGNC:INS)), p(HGNC:INS)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for a(CHEBI:seliciclib), a(CHEBI:\"EC 2.7.11.22 (cyclin-dependent kinase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 24313, 'relation': 'isA', 'evidence': 'Drugs like roscovitine, flavopiridol, calpain inhibitors, kenpaullone and induribins, which inhibit cdk5/p25 formation, constitute potential drugs for the treatment of neurological disorders.', 'citation': {'type': 'PubMed', 'reference': '17160145'}, 'annotations': {'Species': {'9606': True}, 'MeSHDisease': {'Nervous System Diseases': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"exendin-4\"), a(CHEBI:\"glucagon-like peptide-1 receptor agonist\")\n",
      "WARNING:root:  with edge data {'line': 10292, 'relation': 'isA', 'evidence': 'One promising intervention is the use of the incretin hormone glucagon-like peptide-1 (GLP-1) as a treatment for neurodegenerative diseases [25] and [34]. GLP-1 enhances glucose-dependent insulin secretion and lowers blood glucose in subjects with T2DM [15]. Currently, the GLP-1 receptor agonist exenatide (Byetta) is approved for the treatment of T2DM, and many other GLP-1 analogues are in late stage clinical trials. GLP-1 also plays important roles in the brain. The GLP-1 receptor is expressed in neurons [19], and GLP-1 has growth factor-like properties and protects neurons from kainate-induced neurotoxicity [13] and [33], and of the effects of reduced NGF levels [3]. GLP-1 also reduces the induction of apoptosis of hippocampal neurons [13]', 'citation': {'type': 'PubMed', 'reference': '19573562'}, 'annotations': {'Subgraph': {'Glucagon subgraph': True, 'Insulin signal transduction': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for p(SFAM:\"IRS Family\"), p(HGNC:IRS4)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"IRS Family\"), p(HGNC:IRS2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"IRS Family\"), p(HGNC:IRS1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:PPP2CA), complex(p(HGNC:GSK3B), p(HGNC:PPP2CA))\n",
      "WARNING:root:  with edge data {'line': 11087, 'relation': 'isA', 'evidence': 'In SHSY5Y cells, a human neuroblastoma cell line, as well as in primary cultu res of rat cortical neurons insulin administration leads to tau hyperphosphorylation (111-113]. In contrast, insulin and IGF- 1 administration in NT2N cells, cultured human neurons, decreases tau phosphorylation [114]. In primary cortical neuron cultures, M esk e et a/ . (115J found that insulin treatment causes a regulatory interaction between PP2A and GSK-3. Inhibition of Pl3-kinase leads to activat ion of GSK-3and PP2A. Enzyme activity of both enzymes al ways changed in the same direction. This balÂ\\xad anced response seemed to induce a steady state in tau phosÂ\\xad phorylation at GSK-3/PP2A-dependent sites (115]. Thus, on ly a dysbalance of insulin/IGF-1 regulated tau kinases and phosphatases might lead to tau hyperphosphorylation, partially explaining the different resu lts obtained under different conditions.', 'citation': {'type': 'PubMed', 'reference': '19519303'}, 'annotations': {'Subgraph': {'Phosphatidylinositol 3 subgraph': True, 'GSK3 subgraph': True}, 'Confidence': {'High': True}}, 'subject': {'modifier': 'Activity'}}\n",
      "WARNING:root:No converter found for m(HGNC:MIR20A), m(HGNC:MIR17)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for m(HGNC:MIR20A), m(HGNC:MIR106B)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for g(HGNC:A2M), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 12327, 'relation': 'causesNoChange', 'evidence': 'A2M allele and genotype frequencies were similar between AD patients and controls, also after stratification for late onset (≥70 years) and early onset (<70 years) or APOE epsilon4 status. However, there was evidence in support of LD between the OLR1 + 1071, the OLR1 + 1073, and the rs669 SNPs, with T-C-A haplotype being associated with significant increased risk of AD in both the whole sample and when we stratified according to early and late onset AD subjects, with the allelic association with AD predominantly from the OLR1 + 1073 SNP, further supporting the role of OLR1 as a candidate risk gene for sporadic AD.', 'citation': {'type': 'PubMed', 'name': 'Neurobiol Aging. 2009 Sep;30(9):1518-20. Epub 2008 Jan 10.', 'reference': '18191876'}, 'annotations': {'Subgraph': {'Low density lipoprotein subgraph': True, 'Alpha 2 macroglobulin subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for p(FPLX:HSPA), p(HGNC:HSPA1A)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(FPLX:HSPA), p(HGNC:HSPA1B)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(FPLX:HSPA), p(HGNC:HSPA1L)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(a(HBP:\"sAPP-alpha\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(a(HBP:\"sAPP-alpha\"))), a(HBP:\"sAPP-alpha\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for bp(HBP:amyloidogenesis), path(MESHD:\"Neurodegenerative Diseases\")\n",
      "WARNING:root:  with edge data {'line': 69201, 'relation': 'biomarkerFor', 'evidence': 'PP2A dysfunction has been linked to tau hyperphosphorylation, amyloidogenesis and synaptic deficits that are pathological hallmarks of this neurodegenerative disorder.', 'citation': {'type': 'PubMed', 'reference': '24653673'}, 'annotations': {'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:liraglutide), a(CHEBI:\"glucagon-like peptide-1 receptor agonist\")\n",
      "WARNING:root:  with edge data {'line': 14632, 'relation': 'isA', 'evidence': 'Liraglutide (Victoza) and exenatide (Byetta) are novel long-lasting analogues of the GLP-1 incretin hormone and are currently available to treat diabetes.', 'citation': {'type': 'PubMed', 'reference': '22443187'}, 'annotations': {'Subgraph': {'Glucagon subgraph': True, 'Insulin signal transduction': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:lixisenatide), a(CHEBI:\"glucagon-like peptide-1 receptor agonist\")\n",
      "WARNING:root:  with edge data {'line': 14662, 'relation': 'isA', 'evidence': 'Liraglutide and lixisenatide enhanced cAMP levels in the brain, with lixisenatide being more effective.Our results suggest that these novel incretin analogues cross the BBB and show physiological activity and neurogenesis in the brain, which may be of use as a treatment of neurodegenerative diseases.', 'citation': {'type': 'PubMed', 'reference': '22443187'}, 'annotations': {'MeSHDisease': {'Neurodegenerative Diseases': True}, 'MeSHAnatomy': {'Brain': True}, 'Subgraph': {'Glucagon subgraph': True, 'Insulin signal transduction': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for g(DBSNP:rs1887922), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 14908, 'relation': 'causesNoChange', 'evidence': \"Several genetic association studies examined IDE gene as a susceptibility gene for Alzheimer's disease (AD), however with controversial results.We examined associations of three IDE polymorphisms (IDE2, rs4646953; IDE7, rs2251101 and IDE9, rs1887922) with AD, Abeta42 plasma level and T2DM risk in the longitudinal Vienna Transdanube Aging (VITA) study cohort.The upstream polymorphism IDE2 was found to influence AD risk and to trigger the Abeta42 plasma level, whereas the downstream polymorphism IDE7 modified the T2DM risk; no associations were found for the intronic variant IDE9.Based on our SNP and haplotype results, we delineate the model that IDE promoter and 3' untranslated region/downstream variation may have different effects on IDE expression, presumably a relevant endophenotype with disorder-specific effects on AD and T2DM susceptibility.\", 'citation': {'type': 'PubMed', 'name': 'BMC Med Genet. 2011 Nov 22;12:151. doi: 10.1186/1471-2350-12-151.', 'reference': '22107728'}, 'annotations': {'Subgraph': {'Amyloidogenic subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for g(DBSNP:rs1887922), path(MESHD:\"Diabetes Mellitus, Type 2\")\n",
      "WARNING:root:  with edge data {'line': 14909, 'relation': 'causesNoChange', 'evidence': \"Several genetic association studies examined IDE gene as a susceptibility gene for Alzheimer's disease (AD), however with controversial results.We examined associations of three IDE polymorphisms (IDE2, rs4646953; IDE7, rs2251101 and IDE9, rs1887922) with AD, Abeta42 plasma level and T2DM risk in the longitudinal Vienna Transdanube Aging (VITA) study cohort.The upstream polymorphism IDE2 was found to influence AD risk and to trigger the Abeta42 plasma level, whereas the downstream polymorphism IDE7 modified the T2DM risk; no associations were found for the intronic variant IDE9.Based on our SNP and haplotype results, we delineate the model that IDE promoter and 3' untranslated region/downstream variation may have different effects on IDE expression, presumably a relevant endophenotype with disorder-specific effects on AD and T2DM susceptibility.\", 'citation': {'type': 'PubMed', 'name': 'BMC Med Genet. 2011 Nov 22;12:151. doi: 10.1186/1471-2350-12-151.', 'reference': '22107728'}, 'annotations': {'Subgraph': {'Amyloidogenic subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:HEXB), path(MESHD:\"Diabetes Mellitus, Type 2\")\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 14977, 'relation': 'biomarkerFor', 'evidence': 'Statistical analyses based on ROC curves showed that both beta-Galactosidase and beta-Hexosaminidase activities, either intracellular or plasma-secreted, may be used to discriminate AD patients from controls and AD-T2DM from T2DM patients.', 'citation': {'type': 'PubMed', 'reference': '21321400'}, 'annotations': {'CellStructure': {'Lysosomes': True}, 'MeSHAnatomy': {'Plasma': True}, 'Confidence': {'Medium': True}, 'MeSHDisease': {'Alzheimer Disease': True}}, 'subject': {'modifier': 'Activity'}}\n",
      "WARNING:root:No converter found for p(HGNC:HEXB), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 14973, 'relation': 'biomarkerFor', 'evidence': 'Statistical analyses based on ROC curves showed that both beta-Galactosidase and beta-Hexosaminidase activities, either intracellular or plasma-secreted, may be used to discriminate AD patients from controls and AD-T2DM from T2DM patients.', 'citation': {'type': 'PubMed', 'reference': '21321400'}, 'annotations': {'CellStructure': {'Lysosomes': True}, 'MeSHAnatomy': {'Plasma': True}, 'Confidence': {'Medium': True}}, 'subject': {'modifier': 'Activity'}}\n",
      "WARNING:root:No converter found for p(HGNC:GLB1), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 14972, 'relation': 'biomarkerFor', 'evidence': 'Statistical analyses based on ROC curves showed that both beta-Galactosidase and beta-Hexosaminidase activities, either intracellular or plasma-secreted, may be used to discriminate AD patients from controls and AD-T2DM from T2DM patients.', 'citation': {'type': 'PubMed', 'reference': '21321400'}, 'annotations': {'CellStructure': {'Lysosomes': True}, 'MeSHAnatomy': {'Plasma': True}, 'Confidence': {'Medium': True}}, 'subject': {'modifier': 'Activity'}}\n",
      "WARNING:root:No converter found for p(HGNC:GLB1), path(MESHD:\"Diabetes Mellitus, Type 2\")\n",
      "WARNING:root:  with edge data {'line': 14976, 'relation': 'biomarkerFor', 'evidence': 'Statistical analyses based on ROC curves showed that both beta-Galactosidase and beta-Hexosaminidase activities, either intracellular or plasma-secreted, may be used to discriminate AD patients from controls and AD-T2DM from T2DM patients.', 'citation': {'type': 'PubMed', 'reference': '21321400'}, 'annotations': {'CellStructure': {'Lysosomes': True}, 'MeSHAnatomy': {'Plasma': True}, 'Confidence': {'Medium': True}, 'MeSHDisease': {'Alzheimer Disease': True}}, 'subject': {'modifier': 'Activity'}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"5-chloro-7-iodoquinolin-8-ol\"), a(CHEBI:\"proteasome inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 20597, 'relation': 'isA', 'evidence': \"5-chloro-7-iodoquinolin-8-ol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptotic process-inducing, and antitumor activities in human prostate cancer cells and xenografts.\", 'citation': {'type': 'PubMed', 'reference': '17308104'}, 'annotations': {'MeSHDisease': {'Alzheimer Disease': True, 'Prostatic Neoplasms': True}, 'MeSHAnatomy': {'Prostate': True}, 'Species': {'9606': True}, 'Subgraph': {'Androgen subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for a(MESHC:Butyrylcholinesterase), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 15134, 'relation': 'biomarkerFor', 'evidence': \"Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease.\", 'citation': {'type': 'PubMed', 'reference': '17553629'}}\n",
      "WARNING:root:No converter found for a(MESHC:Acetylcholinesterase), path(MESHD:\"Diabetes Mellitus, Type 2\")\n",
      "WARNING:root:  with edge data {'line': 15135, 'relation': 'biomarkerFor', 'evidence': \"Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease.\", 'citation': {'type': 'PubMed', 'reference': '17553629'}}\n",
      "WARNING:root:No converter found for a(MESHC:lipopigments), a(CHEBI:\"biological pigment\")\n",
      "WARNING:root:  with edge data {'line': 15999, 'relation': 'isA', 'evidence': 'Lipopigment, identifiable in the fluorescence microscope, is thought to be cellular debris partly derived from free-radical-induced peroxidation of cellular constituents. The volume of neuronal lipopigment has been positively correlated with advancing age, Alzheimer dementia, and the neuronal ceroidoses. Chronic administration of agents which can be correlated with decreased neuronal lipopigment in animal models might protect neuronal function against any adverse effects associated with (but not necessarily resulting from) lipopigment accumulation in normal ageing, anoxia, or certain degenerative diseases.', 'citation': {'type': 'PubMed', 'name': 'Br J Psychiatry. 1989 Jul;155:1-11', 'reference': '2690998'}, 'annotations': {'MeSHAnatomy': {'Neurons': True}, 'Subgraph': {'Dopaminergic subgraph': True, 'Serotonergic subgraph': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"ergoloid mesylate\"), a(CHEBI:\"vasodilator agent\")\n",
      "WARNING:root:  with edge data {'line': 16014, 'relation': 'isA', 'evidence': 'Ergoloid mesylate is a dihydrogenated ergot (Claviceps purpurea) derivative alkaloid used as a vasodilator agent. Ergoloid Mesylate is the only vasodilator that has shown mild benefits in the treatment of vascular dementia.', 'citation': {'type': 'Online Resource', 'name': 'AD_HBP', 'reference': 'DB01049'}, 'annotations': {'Subgraph': {'Dopaminergic subgraph': True, 'Serotonergic subgraph': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"ergoloid mesylate\"), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 16027, 'relation': 'causesNoChange', 'evidence': \"Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.\", 'citation': {'type': 'Online Resource', 'name': 'AD_HBP', 'reference': 'DB01049'}, 'annotations': {'Subgraph': {'Dopaminergic subgraph': True, 'Serotonergic subgraph': True}, 'MeSHAnatomy': {'Cerebrum': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"ergoloid mesylate\"), a(CHEBI:\"alpha-adrenergic antagonist\")\n",
      "WARNING:root:  with edge data {'line': 16037, 'relation': 'isA', 'evidence': 'Ergoloid mesylates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels.', 'citation': {'type': 'Online Resource', 'name': 'AD_HBP', 'reference': 'DB01049'}, 'annotations': {'Subgraph': {'Dopaminergic subgraph': True, 'Serotonergic subgraph': True}, 'MeSHAnatomy': {'Cerebrum': True}}}\n",
      "WARNING:root:No converter found for p(SFAM:\"ADRA Family\"), p(HGNC:ADRA1A)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"ADRA Family\"), p(HGNC:ADRA1B)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"ADRA Family\"), p(HGNC:ADRA1D)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"ADRA Family\"), p(HGNC:ADRA2A)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"ADRA Family\"), p(HGNC:ADRA2B)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"ADRA Family\"), p(HGNC:ADRA2C)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:EDN1), a(CHEBI:\"vasoconstrictor agent\")\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 16081, 'relation': 'isA', 'evidence': 'Our results show that freshly solubilized Abeta1Ã¢â‚¬ 40 enhances the vasoconstriction induced by endothelin-1 (ET-1) and increases resistance to relaxation triggered by nitric oxide (NO), suggesting that Abeta may oppose the NO/cGMP pathway. Using specific inhibitors and activators of the NO/cGMP pathway, we show that Abeta vasoactivity is not due to a modulation of nitric oxide synthase (NOS) or soluble guanylyl cyclase (sGC). However, we find that a selective cGMP phosphodiesterase (cGMP-PDE) inhibitor (dipyridamole) is able to interactively block the enhanced vasoconstriction as well as the opposition to relaxation induced by Abeta, suggesting that Abeta could effect the activity of this enzyme. Cyclic GMP levels, but not cAMP concentrations, are reduced after Abeta treatment of rat aortic rings, further substantiating this hypothesis.', 'citation': {'type': 'PubMed', 'reference': '10222124'}, 'annotations': {'Subgraph': {'Blood vessel dilation subgraph': True, 'Endothelin subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:EDN1), a(CHEBI:\"vasoconstrictor agent\")\n",
      "WARNING:root:  with edge data {'line': 24939, 'relation': 'isA', 'evidence': 'In the brain, endothelin-1 (ET-1) is a locally acting vasoconstrictor, produced in neurons by endothelin-converting enzyme (ECE)-2 and in endothelial cells by ECE-1.', 'citation': {'type': 'PubMed', 'name': 'J Alzheimers Dis. 2013;36(3):577-87', 'reference': '23629587'}, 'annotations': {'MeSHAnatomy': {'Neurons': True}, 'Subgraph': {'Endothelin subgraph': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:dipyridamole), a(CHEBI:\"EC 3.1.4.* (phosphoric diester hydrolase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 16088, 'relation': 'isA', 'evidence': 'Our results show that freshly solubilized Abeta1Ã¢â‚¬ 40 enhances the vasoconstriction induced by endothelin-1 (ET-1) and increases resistance to relaxation triggered by nitric oxide (NO), suggesting that Abeta may oppose the NO/cGMP pathway. Using specific inhibitors and activators of the NO/cGMP pathway, we show that Abeta vasoactivity is not due to a modulation of nitric oxide synthase (NOS) or soluble guanylyl cyclase (sGC). However, we find that a selective cGMP phosphodiesterase (cGMP-PDE) inhibitor (dipyridamole) is able to interactively block the enhanced vasoconstriction as well as the opposition to relaxation induced by Abeta, suggesting that Abeta could effect the activity of this enzyme. Cyclic GMP levels, but not cAMP concentrations, are reduced after Abeta treatment of rat aortic rings, further substantiating this hypothesis.', 'citation': {'type': 'PubMed', 'reference': '10222124'}, 'annotations': {'Subgraph': {'Blood vessel dilation subgraph': True, 'Endothelin subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(MESHC:cerebrolysin), p(HGNC:BDNF)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(MESHC:cerebrolysin), p(HGNC:GDNF)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(MESHC:cerebrolysin), p(HGNC:NGF)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(MESHC:cerebrolysin), p(HGNC:CNTF)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(MESHC:cerebrolysin), p(MGI:Bace1)\n",
      "WARNING:root:  with edge data {'line': 16223, 'relation': 'causesNoChange', 'evidence': \"Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated.\", 'citation': {'type': 'PubMed', 'reference': '16511867'}, 'annotations': {'Species': {'10090': True}, 'Subgraph': {'Beta secretase subgraph': True, 'Nerve growth factor subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(MESHC:cerebrolysin), p(MGI:Notch1)\n",
      "WARNING:root:  with edge data {'line': 16231, 'relation': 'causesNoChange', 'evidence': \"Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated.\", 'citation': {'type': 'PubMed', 'reference': '16511867'}, 'annotations': {'Species': {'10090': True}, 'Subgraph': {'Notch signaling subgraph': True, 'Nerve growth factor subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(MESHC:cerebrolysin), p(MGI:Mme)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 16232, 'relation': 'causesNoChange', 'evidence': \"Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated.\", 'citation': {'type': 'PubMed', 'reference': '16511867'}, 'annotations': {'Species': {'10090': True}, 'Subgraph': {'Notch signaling subgraph': True, 'Nerve growth factor subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(MESHC:cerebrolysin), p(MGI:Ide)\n",
      "WARNING:root:  with edge data {'line': 16234, 'relation': 'causesNoChange', 'evidence': \"Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated.\", 'citation': {'type': 'PubMed', 'reference': '16511867'}, 'annotations': {'Species': {'10090': True}, 'Subgraph': {'Notch signaling subgraph': True, 'Nerve growth factor subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:donepezil), a(CHEBI:\"EC 3.1.1.7 (acetylcholinesterase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 16397, 'relation': 'isA', 'evidence': \"Deficit in central cholinergic neurotransmission is a consistent change associated with Alzheimer's disease (AD). Donepezil hydrochloride exhibits selective inhibition of acetylcholinesterase (AChE) and is widely used for the treatment of AD.\", 'citation': {'type': 'PubMed', 'name': 'Br J Clin Pharmacol. 2008 Apr;65(4):472-9', 'reference': '18070217'}, 'annotations': {'Subgraph': {'Acetylcholine signaling subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:donepezil), a(CHEBI:\"EC 3.1.1.7 (acetylcholinesterase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 16467, 'relation': 'isA', 'evidence': 'Alzheimer disease (AD) is associated with a decreased APP forms ratio (APPr) between the three major forms. This study demonstrated that donepezil, a drug acting as an inhibitor of acetylcholinesterase, affects APP metabolism in Alzheimer disease, restoring the ratio of APP forms in platelets up to the normal range after 4 weeks of treatment.', 'citation': {'type': 'PubMed', 'name': 'Eur Neuropsychopharmacol. 2002 Jun;12(3):195-200', 'reference': '12007670'}, 'annotations': {'Subgraph': {'Non-amyloidogenic subgraph': True, 'Acetylcholine signaling subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:donepezil), a(CHEBI:\"reactive oxygen species\")\n",
      "WARNING:root:  with edge data {'line': 28076, 'relation': 'causesNoChange', 'evidence': 'Production of reactive oxygen species (ROS) in brain regions was measured relative to control. There was a significant increase (P<0.01) in ROS level in cerebellum, hippocampus, cortex and striatum of OKA 200 ng treated rats as compared to control group. Treatment with memantine significantly (Pb0.05) reduced the amount of ROS whereas donepezil did not show significant (PN0.05) effect in any brain regions.', 'citation': {'type': 'PubMed', 'reference': '21893081'}, 'annotations': {'Species': {'10116': True}, 'MeSHAnatomy': {'Cerebral Cortex': True, 'Cerebellum': True, 'Hippocampus': True}, 'Subgraph': {'Reactive oxygen species subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:rivastigmine), a(CHEBI:\"EC 3.1.1.7 (acetylcholinesterase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 16565, 'relation': 'isA', 'evidence': \"Rivastigmine tartrate is a reversible cholinesterase inhibitor indicated for the symptomatic treatment of mild to moderate dementia. Rivastigmine has been shown to improve or maintain patients' performance in 3 major domains: cognitive function, global function (ADLs), and behavior.\", 'citation': {'type': 'PubMed', 'reference': '12860489'}, 'annotations': {'Subgraph': {'Acetylcholine signaling subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:rivastigmine), p(HGNC:GSR)\n",
      "WARNING:root:  with edge data {'line': 24656, 'relation': 'causesNoChange', 'evidence': 'Depending on the treatment received, a distinct inflammatory and oxidative stress profile was observed: in Rivastigmine-treated group, IL6 levels were 47% lower than the average value of the remaining AD patients; homocysteine and glutathione reductase were statistically unchanged in the Rivastigmine and Donepezil-Memantine, respectively Donepezil group.', 'citation': {'type': 'PubMed', 'name': 'Food Chem Toxicol. 2013 Nov;61:209-14', 'reference': '23871825'}, 'annotations': {'Species': {'9606': True}, 'Subgraph': {'Glutathione reductase subgraph': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:rivastigmine), p(HGNC:APP)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 29042, 'relation': 'causesNoChange', 'evidence': 'Over the last several years a number of reports have emerged suggesting that at least some ChEI might take part in betaAPP metabolism, influencing its secretion and Abeta differential cleavage. Moreover, we (Sob6w and Kloszewska 2005) and others (Basun et al. 2002, Zimmermann et al. 2005) have shown that the treatment with ChEI might influence BAPP metabolism in AD patients as measured by changes in plasma (including platelet-derived) metabolites. In our previous pilot study we have demonstrated that short-term treatment with ChEI rivastigmine exhibits a significant effect on plasma concentrations of Abeta-42 (mean increase after treatment reached 7.8 Â± 8.4 pg/ml) with a negative correlation to patients age, while no changes in Abeta-40 levels were detected.', 'citation': {'type': 'PubMed', 'name': 'Acta Neurobiol Exp (Wars). 2007;67(2):131-9', 'reference': '17691220'}, 'annotations': {'Species': {'10116': True}, 'Confidence': {'Medium': True}, 'Subgraph': {'Amyloidogenic subgraph': True}, 'MeSHAnatomy': {'Plasma': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:rivastigmine), p(HGNC:IL10)\n",
      "WARNING:root:  with edge data {'line': 29257, 'relation': 'causesNoChange', 'evidence': 'Rivastigmine decreased the reactivity of encephalitogenic T-cells and the production of pro-inflammatory cytokines (TNF-Î±, IFN-gamma and IL-17) without affecting IL-10 production.', 'citation': {'type': 'PubMed', 'reference': '18692909'}, 'annotations': {'Subgraph': {'Interleukin signaling subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:galanthamine), a(CHEBI:\"EC 3.1.1.7 (acetylcholinesterase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 16641, 'relation': 'isA', 'evidence': \"Galantamine is a phenanthrene alkaloid (similar to codeine) and acts as a reversible inhibitor of AChE with a competitive action. In addition, galantamine's nicotinic agonist properties may provide an additional therapeutic mechanism to AChE inhibition.\", 'citation': {'type': 'PubMed', 'name': 'Brain Res Mol Brain Res. 2004 Nov 24;131(1-2):136-40', 'reference': '15530663'}, 'annotations': {'Subgraph': {'Acetylcholine signaling subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:galanthamine), a(CHEBI:\"nicotinic acetylcholine receptor agonist\")\n",
      "WARNING:root:  with edge data {'line': 16649, 'relation': 'isA', 'evidence': \"Galantamine is a phenanthrene alkaloid (similar to codeine) and acts as a reversible inhibitor of AChE with a competitive action. In addition, galantamine's nicotinic agonist properties may provide an additional therapeutic mechanism to AChE inhibition.\", 'citation': {'type': 'PubMed', 'name': 'Brain Res Mol Brain Res. 2004 Nov 24;131(1-2):136-40', 'reference': '15530663'}, 'annotations': {'Subgraph': {'Acetylcholine signaling subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:memantine), a(CHEBI:\"NMDA receptor antagonist\")\n",
      "WARNING:root:  with edge data {'line': 16731, 'relation': 'isA', 'evidence': \"Memantine (Ebixa, Namenda, Axura) is an uncompetitive NMDA receptor antagonist used in the management of patients with moderate-to-severe Alzheimer's disease.\", 'citation': {'type': 'PubMed', 'name': 'Pharmacoeconomics. 2005;23(2):193-206', 'reference': '15748093'}, 'annotations': {'Subgraph': {'NMDA receptor': True, 'Glutamatergic subgraph': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:fluvoxamine), a(CHEBI:\"serotonin uptake inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 16819, 'relation': 'isA', 'evidence': \"We report on two cases in which monotherapy of the selective serotonin reuptake inhibitor and sigma-1 receptor agonist fluvoxamine was effective in ameliorating the delirium of patients with Alzheimer's disease.\", 'citation': {'type': 'PubMed', 'name': 'Ann Gen Psychiatry. 2010 Jan 20;9:6', 'reference': '20148109'}, 'annotations': {'Species': {'9606': True}, 'Subgraph': {'NMDA receptor': True, 'Glutamatergic subgraph': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:fluvoxamine), a(CHEBI:antidepressant)\n",
      "WARNING:root:  with edge data {'line': 16923, 'relation': 'isA', 'evidence': 'The antidepressant fluvoxamine, the drug of abuse methamphetamine, and the neurosteroid progesterone were amongst the many ligands whose interactions with the sigma(1) receptor were confirmed with our screening assay.', 'citation': {'type': 'PubMed', 'name': 'Eur J Pharmacol. 2008 Jan 14;578(2-3):123-36', 'reference': '17961544'}}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"antipsychotic agent\"), a(CHEBI:\"lithium atom\")), a(CHEBI:\"antipsychotic agent\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"antipsychotic agent\"), a(CHEBI:\"lithium atom\")), a(CHEBI:\"lithium atom\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for a(CHEBI:etazolate), a(CHEBI:\"GABA modulator\")\n",
      "WARNING:root:  with edge data {'line': 16964, 'relation': 'isA', 'evidence': 'In this study, we show that at nanomolar-low micromolar concentrations, etazolate, a selective GABA(A) receptor modulator, stimulates sAPPalpha production in rat cortical neurons and in guinea pig brains. Etazolate (20 nM-2 microM) dose-dependently protected rat cortical neurons against Abeta-induced toxicity. The neuroprotective effects of etazolate were fully blocked by GABA(A) receptor antagonists indicating that this neuroprotection was due to GABA(A) receptor signalling. This indicating that etazolate exerts its neuroprotective effect via sAPPalpha induction.', 'citation': {'type': 'PubMed', 'reference': '18397369'}, 'annotations': {'Species': {'10116': True}, 'MeSHAnatomy': {'Neurons': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:etazolate), a(CHEBI:\"GABA modulator\")\n",
      "WARNING:root:  with edge data {'line': 17966, 'relation': 'isA', 'evidence': \"EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer's Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.\", 'citation': {'type': 'PubMed', 'name': 'Curr Alzheimer Res. 2011 Mar;8(2):203-12', 'reference': '21222604'}, 'annotations': {'FDASTATUS': {'Phase 2': True}, 'Species': {'9606': True}, 'Subgraph': {'GABA subgraph': True, 'Non-amyloidogenic subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:etazolate), a(CHEBI:\"EC 3.1.4.* (phosphoric diester hydrolase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 17926, 'relation': 'isA', 'evidence': \"Etazolate is a phosphodiesterase 4 (PDE4) inhibitor and GABAA receptor modulator that also stimulates alpha-secretase activity and neurotrophic soluble amyloid precursor protein (sAPPalpha) production, currently developed as a possible Alzheimer's disease therapeutic.\", 'citation': {'type': 'PubMed', 'name': 'Eur J Pharmacol. 2010 May 25;634(1-3):95-100', 'reference': '20223232'}, 'annotations': {'Species': {'10116': True}, 'Subgraph': {'GABA subgraph': True, 'Non-amyloidogenic subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:etazolate), a(CHEBI:\"EC 3.1.4.* (phosphoric diester hydrolase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 17969, 'relation': 'isA', 'evidence': \"EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer's Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.\", 'citation': {'type': 'PubMed', 'name': 'Curr Alzheimer Res. 2011 Mar;8(2):203-12', 'reference': '21222604'}, 'annotations': {'FDASTATUS': {'Phase 2': True}, 'Species': {'9606': True}, 'Subgraph': {'GABA subgraph': True, 'Non-amyloidogenic subgraph': True}, 'Confidence': {'High': True}}}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:No converter found for a(CHEBI:atropine), a(CHEBI:\"muscarinic antagonist\")\n",
      "WARNING:root:  with edge data {'line': 17259, 'relation': 'isA', 'evidence': 'The action of arecoline on rat locus coeruleus neurons was studied by intracellular recording from the in vitro brain slice preparation. The arecoline-induced excitatory effects were antagonized by the muscarinic receptor antagonist, atropine, but not by the nicotinic receptor antagonist, hexamethonium. Methoctramine, a selective M2-muscarinic receptor antagonist, was also effective in reversing the arecoline-induced effects.', 'citation': {'type': 'PubMed', 'name': 'Chin J Physiol. 2000 Mar 31;43(1):23-8', 'reference': '10857465'}, 'annotations': {'Species': {'10116': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:methoctramine), a(CHEBI:\"muscarinic antagonist\")\n",
      "WARNING:root:  with edge data {'line': 17263, 'relation': 'isA', 'evidence': 'The action of arecoline on rat locus coeruleus neurons was studied by intracellular recording from the in vitro brain slice preparation. The arecoline-induced excitatory effects were antagonized by the muscarinic receptor antagonist, atropine, but not by the nicotinic receptor antagonist, hexamethonium. Methoctramine, a selective M2-muscarinic receptor antagonist, was also effective in reversing the arecoline-induced effects.', 'citation': {'type': 'PubMed', 'name': 'Chin J Physiol. 2000 Mar 31;43(1):23-8', 'reference': '10857465'}, 'annotations': {'Species': {'10116': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:Hexamethonium), a(CHEBI:\"nicotinic antagonist\")\n",
      "WARNING:root:  with edge data {'line': 17267, 'relation': 'isA', 'evidence': 'The action of arecoline on rat locus coeruleus neurons was studied by intracellular recording from the in vitro brain slice preparation. The arecoline-induced excitatory effects were antagonized by the muscarinic receptor antagonist, atropine, but not by the nicotinic receptor antagonist, hexamethonium. Methoctramine, a selective M2-muscarinic receptor antagonist, was also effective in reversing the arecoline-induced effects.', 'citation': {'type': 'PubMed', 'name': 'Chin J Physiol. 2000 Mar 31;43(1):23-8', 'reference': '10857465'}, 'annotations': {'Species': {'10116': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:Hexamethonium), a(CHEBI:arecoline)\n",
      "WARNING:root:  with edge data {'line': 17298, 'relation': 'causesNoChange', 'evidence': 'The action of arecoline on rat locus coeruleus neurons was studied by intracellular recording from the in vitro brain slice preparation. The arecoline-induced excitatory effects were antagonized by the muscarinic receptor antagonist, atropine, but not by the nicotinic receptor antagonist, hexamethonium. Methoctramine, a selective M2-muscarinic receptor antagonist, was also effective in reversing the arecoline-induced effects.', 'citation': {'type': 'PubMed', 'name': 'Chin J Physiol. 2000 Mar 31;43(1):23-8', 'reference': '10857465'}, 'annotations': {'Species': {'10116': True}}, 'object': {'modifier': 'Activity'}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"nicotinic antagonist\"), a(CHEBI:arecoline)\n",
      "WARNING:root:  with edge data {'line': 17296, 'relation': 'causesNoChange', 'evidence': 'The action of arecoline on rat locus coeruleus neurons was studied by intracellular recording from the in vitro brain slice preparation. The arecoline-induced excitatory effects were antagonized by the muscarinic receptor antagonist, atropine, but not by the nicotinic receptor antagonist, hexamethonium. Methoctramine, a selective M2-muscarinic receptor antagonist, was also effective in reversing the arecoline-induced effects.', 'citation': {'type': 'PubMed', 'name': 'Chin J Physiol. 2000 Mar 31;43(1):23-8', 'reference': '10857465'}, 'annotations': {'Species': {'10116': True}}, 'object': {'modifier': 'Activity'}}\n",
      "WARNING:root:No converter found for a(CHEBI:arecoline), a(CHEBI:\"muscarinic agonist\")\n",
      "WARNING:root:  with edge data {'line': 17321, 'relation': 'isA', 'evidence': 'Physostigmine, an acetyl cholinesterase inhibitor, and arecoline, a muscarinic agonist, have been shown to improve Alzheimer presenile dementia in some patients when administered parenterally. Both of these compounds are ineffective orally due to first-pass metabolism.', 'citation': {'type': 'PubMed', 'name': 'J Pharm Sci. 1991 Aug;80(8):750-1', 'reference': '1791534'}, 'annotations': {'Species': {'10116': True}, 'Subgraph': {'Acetylcholine signaling subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:arecoline), a(CHEBI:\"cholinergic agonist\")\n",
      "WARNING:root:  with edge data {'line': 17453, 'relation': 'isA', 'evidence': 'The hypothalamic-pituitary-adrenal (HPA) axis is regulated by cholinergic mechanisms. Acetylcholine (ACh), the cholinergic neurotransmitter, has been reported to alter the levels of cortisol as well as those of prolactin, growth hormone, leutinizing hormone and vasopressin. Prolactin secretion, however, is suppressed by increased pure cholinergic activity. Central actions of cholinomimetic drugs that either increase the concentration of ACh in brain (e.g. physostigmine) or activate the postsynaptic muscarinic receptors (e.g. arecoline), can also activate the HPA axis in both animals and human subjects.', 'citation': {'type': 'PubMed', 'reference': '8584603'}, 'annotations': {'MeSHAnatomy': {'Brain': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:physostigmine), a(CHEBI:\"EC 3.1.1.8 (cholinesterase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 17325, 'relation': 'isA', 'evidence': 'Physostigmine, an acetyl cholinesterase inhibitor, and arecoline, a muscarinic agonist, have been shown to improve Alzheimer presenile dementia in some patients when administered parenterally. Both of these compounds are ineffective orally due to first-pass metabolism.', 'citation': {'type': 'PubMed', 'name': 'J Pharm Sci. 1991 Aug;80(8):750-1', 'reference': '1791534'}, 'annotations': {'Species': {'10116': True}, 'Subgraph': {'Acetylcholine signaling subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:physostigmine), a(CHEBI:\"cholinergic agonist\")\n",
      "WARNING:root:  with edge data {'line': 17450, 'relation': 'isA', 'evidence': 'The hypothalamic-pituitary-adrenal (HPA) axis is regulated by cholinergic mechanisms. Acetylcholine (ACh), the cholinergic neurotransmitter, has been reported to alter the levels of cortisol as well as those of prolactin, growth hormone, leutinizing hormone and vasopressin. Prolactin secretion, however, is suppressed by increased pure cholinergic activity. Central actions of cholinomimetic drugs that either increase the concentration of ACh in brain (e.g. physostigmine) or activate the postsynaptic muscarinic receptors (e.g. arecoline), can also activate the HPA axis in both animals and human subjects.', 'citation': {'type': 'PubMed', 'reference': '8584603'}, 'annotations': {'MeSHAnatomy': {'Brain': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"(R)-flurbiprofen\"), bp(GOBP:\"regulation of prostaglandin-endoperoxide synthase activity\")\n",
      "WARNING:root:  with edge data {'line': 17603, 'relation': 'causesNoChange', 'evidence': 'Flurbiprofen, the NSAID of which tarenflurbil is the R-enantiomer, has substantial amyloid-reducing activity. Because the R-enantiomer retains this anti-amyloid effect but does not have the cyclo-oxygenase inhibitory effect of flurbiprofen, it can be given at relatively high doses to elderly patients. It is thus a promising candidate for treatment of AD.', 'citation': {'type': 'PubMed', 'name': 'Lancet Neurol. 2008 Jun;7(6):468-9', 'reference': '18450518'}, 'annotations': {'FDASTATUS': {'Phase 2': True}, 'DiseaseState': {'Mild AD': True}, 'Subgraph': {'Inflammatory response subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"(R)-flurbiprofen\"), path(MESHD:\"Alzheimer Disease\")\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 17614, 'relation': 'causesNoChange', 'evidence': 'The phase II trial of tarenflurbil1 was designed to show slowing of cognitive and functional decline in mild to moderate AD, with enrolment of about 200 patients in a 1-year trial. The primary analysis failed: there was no overall effect on the primary outcomes. But planned analyses nonetheless suggested that the drug had an influence on the outcome measures: there was a significant interactive effect of treatment and baseline cognitive function on change in outcomes. Do these results prove the efficacy of tarenflurbil in slowing decline in mild AD? Noâ€”the data are consistent with a beneficial effect of tarenflurbil in mild AD, but are hardly conclusive.', 'citation': {'type': 'PubMed', 'name': 'Lancet Neurol. 2008 Jun;7(6):468-9', 'reference': '18450518'}, 'annotations': {'FDASTATUS': {'Phase 2': True}, 'DiseaseState': {'Mild AD': True}, 'Subgraph': {'Inflammatory response subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"(R)-flurbiprofen\"), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 17653, 'relation': 'causesNoChange', 'evidence': \"A recent report by Green and colleagues3 presents the results of this phase 3 trial of tarenflurbil in patients with mild Alzheimer's disease, in which there were no significant effects on any of the primary endpoints\", 'citation': {'type': 'PubMed', 'name': 'Lancet Neurol. 2010 Mar;9(3):235-7', 'reference': '20170836'}, 'annotations': {'FDASTATUS': {'Phase 3': True}, 'DiseaseState': {'Mild AD': True}, 'Subgraph': {'Inflammatory response subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"(R)-flurbiprofen\"), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 17694, 'relation': 'causesNoChange', 'evidence': 'Tarenflurbil had no beneficial effect on the co-primary outcomes using an intent-to-treat analysis. No significant differences occurred in the secondary outcomes. The ADAS-Cog score decreased by 7.1 points over 18 months. The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections.', 'citation': {'type': 'PubMed', 'name': 'JAMA. 2009 Dec 16;302(23):2557-64', 'reference': '20009055'}, 'annotations': {'FDASTATUS': {'Phase 2': True}, 'DiseaseState': {'Mild AD': True}, 'Subgraph': {'Inflammatory response subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"(R)-flurbiprofen\"), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 17741, 'relation': 'causesNoChange', 'evidence': \"In patients with moderate AD, 800 mg tarenflurbil twice per day had no significant effects on ADCS-ADL and ADAS-cog and had a negative effect on CDR-sb (-52%, Cohen's d -1.08; p=0.003).The most common adverse events were diarrhoea (in seven, nine, and five patients in the 800 mg, 400 mg, and placebo groups, respectively), nausea (in seven, seven, and four patients), and dizziness (in five, nine, and four patients).\", 'citation': {'type': 'PubMed', 'name': 'Lancet Neurol. 2008 Jun;7(6):483-93', 'reference': '18450517'}, 'annotations': {'FDASTATUS': {'Phase 2': True}, 'DiseaseState': {'Mild AD': True}, 'Subgraph': {'Inflammatory response subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"(R)-flurbiprofen\"), a(MESH:D001812)\n",
      "WARNING:root:  with edge data {'line': 17676, 'relation': 'causesNoChange', 'evidence': 'In conclusion, supposing that the Aβ hypothesis of AD is still correct, it is possible that the negative results obtained by tarenflurbil in mild AD patients in the recently completed Phase III study are due to the compound’s poor pharmacological profile as Aβ 1−42 lowering agent, its poor ability to penetrate the blood-brain barrier and to its residual anti-inflammatory activity.', 'citation': {'type': 'PubMed', 'name': 'J Alzheimers Dis. 2009;17(4):757-60', 'reference': '19542625'}, 'annotations': {'FDASTATUS': {'Phase 3': True}, 'DiseaseState': {'Mild AD': True}, 'Subgraph': {'Non-amyloidogenic subgraph': True, 'Inflammatory response subgraph': True, 'Gamma secretase subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"(R)-flurbiprofen\"), a(CHEBI:\"gamma-secretase modulator\")\n",
      "WARNING:root:  with edge data {'line': 17718, 'relation': 'isA', 'evidence': 'The outcomes of the clinical trials of the gamma-secretase inhibitor Semagacestat (LY-450139) and the gamma-secretase modulator (GSM) Tarenflurbil were disappointing, but may not represent the end of the gamma-secretase era. gamma-Secretase modulators, by definition, only block the gamma-secretase cleavage of amyloid-beta protein precursor (AbetaPP) to generate the longer, 42-residue amyloid-beta (Abeta42) without changing the production of total Abeta. The first generation GSMs were shown to block Abeta42 generation while increasing Abeta38. The non-steroidal anti-inflammatory drug, Tarenflurbil, binds to AbetaPP and shifts the cleavage site from Abeta42 to Abeta38', 'citation': {'type': 'PubMed', 'name': 'J Alzheimers Dis. 2012;31(4):685-96', 'reference': '22710916'}, 'annotations': {'FDASTATUS': {'Phase 2': True}, 'DiseaseState': {'Mild AD': True}, 'Subgraph': {'Non-amyloidogenic subgraph': True, 'Inflammatory response subgraph': True, 'Gamma secretase subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"(R)-flurbiprofen\"), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'line': 17673, 'relation': 'causesNoChange', 'evidence': 'In conclusion, supposing that the Aβ hypothesis of AD is still correct, it is possible that the negative results obtained by tarenflurbil in mild AD patients in the recently completed Phase III study are due to the compound’s poor pharmacological profile as Aβ 1−42 lowering agent, its poor ability to penetrate the blood-brain barrier and to its residual anti-inflammatory activity.', 'citation': {'type': 'PubMed', 'name': 'J Alzheimers Dis. 2009;17(4):757-60', 'reference': '19542625'}, 'annotations': {'FDASTATUS': {'Phase 3': True}, 'DiseaseState': {'Mild AD': True}, 'Subgraph': {'Non-amyloidogenic subgraph': True, 'Inflammatory response subgraph': True, 'Gamma secretase subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:NOTCH1)), products(p(HGNC:NOTCH1, frag(\"?\")))), p(HGNC:NOTCH1)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:NOTCH1)), products(p(HGNC:NOTCH1, frag(\"?\")))), p(HGNC:NOTCH1)\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for a(MESHC:Etazolate), a(CHEBI:\"GABA modulator\")\n",
      "WARNING:root:  with edge data {'line': 17880, 'relation': 'isA', 'evidence': 'In this study, we show that at nanomolar-low micromolar concentrations, etazolate, a selective GABA(A) receptor modulator, stimulates sAPPalpha production in rat cortical neurons and in guinea pig brains. Etazolate (20 nM-2 microM) dose-dependently protected rat cortical neurons against Abeta-induced toxicity.', 'citation': {'type': 'PubMed', 'name': 'J Neurochem. 2008 Jul;106(1):392-404', 'reference': '18397369'}, 'annotations': {'Species': {'10116': True}, 'Subgraph': {'GABA subgraph': True}, 'Confidence': {'Medium': True}}, 'subject': {'modifier': 'Activity'}}\n",
      "WARNING:root:No converter found for a(CHEBI:nefiracetam), bp(GOBP:\"protein kinase A signaling\")\n",
      "WARNING:root:  with edge data {'line': 18082, 'relation': 'causesNoChange', 'evidence': 'In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.', 'citation': {'type': 'PubMed', 'name': 'Mol Pharmacol. 2007 Feb;71(2):580-7', 'reference': '17095583'}, 'annotations': {'Subgraph': {'GABA subgraph': True, 'NMDA receptor': True}, 'Confidence': {'High': True}}}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:No converter found for a(CHEBI:nefiracetam), a(CHEBI:\"EC 3.1.1.7 (acetylcholinesterase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 18240, 'relation': 'isA', 'evidence': \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", 'citation': {'type': 'PubMed', 'name': 'Neuroscience. 2009 May 5;160(2):484-91', 'reference': '19272425'}, 'annotations': {'Species': {'10090': True}, 'Subgraph': {'GABA subgraph': True, 'Acetylcholine signaling subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:PRKCA), p(HGNC:PRKCB)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:PRKCA), p(HGNC:PRKCD)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:PRKCA), p(HGNC:PRKCE)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:PRKCA), p(HGNC:PRKCG)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:PRKCA), p(HGNC:PRKCH)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:PRKCA), p(HGNC:PRKCI)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:PRKCA), p(HGNC:PRKCQ)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:PRKCA), p(HGNC:PRKCZ)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(HGNC:NFKB1), p(HGNC:RELA)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for complex(SCOMP:\"Nfkb Complex\"), p(HGNC:RELA)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for complex(SCOMP:\"Nfkb Complex\"), p(HGNC:NFKB1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:IFNG)), p(HGNC:IFNG)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:IFNG)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:PIN1), p(SFAM:\"RAS Family\")), p(HGNC:PIN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:PIN1), p(SFAM:\"RAS Family\")), p(SFAM:\"RAS Family\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for a(CHEBI:\"vitamin C\"), a(CHEBI:antioxidant)\n",
      "WARNING:root:  with edge data {'line': 20026, 'relation': 'isA', 'evidence': 'The results indicated that dietary intake of vitamins A, C, and E may influence blood levels of catalase possibly through their antioxidant effects on free radicals.', 'citation': {'type': 'PubMed', 'reference': '12094909'}, 'annotations': {'MeSHAnatomy': {'Blood': True}, 'Subgraph': {'Vitamin subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"vitamin A\"), a(CHEBI:antioxidant)\n",
      "WARNING:root:  with edge data {'line': 20025, 'relation': 'isA', 'evidence': 'The results indicated that dietary intake of vitamins A, C, and E may influence blood levels of catalase possibly through their antioxidant effects on free radicals.', 'citation': {'type': 'PubMed', 'reference': '12094909'}, 'annotations': {'MeSHAnatomy': {'Blood': True}, 'Subgraph': {'Vitamin subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"vitamin E\"), a(CHEBI:antioxidant)\n",
      "WARNING:root:  with edge data {'line': 20027, 'relation': 'isA', 'evidence': 'The results indicated that dietary intake of vitamins A, C, and E may influence blood levels of catalase possibly through their antioxidant effects on free radicals.', 'citation': {'type': 'PubMed', 'reference': '12094909'}, 'annotations': {'MeSHAnatomy': {'Blood': True}, 'Subgraph': {'Vitamin subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"huperzine A\"), a(CHEBI:\"EC 3.1.1.8 (cholinesterase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 20738, 'relation': 'isA', 'evidence': \"Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A. Huperzine A is a reversible and selective cholinesterase inhibitor approved for the treatment of Alzheimer's disease.\", 'citation': {'type': 'PubMed', 'name': 'Eur J Pharmacol. 2003 Feb 14;461(2-3):89-92', 'reference': '12586202'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Subgraph': {'Cholesterol metabolism subgraph': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:MPO), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 23577, 'relation': 'causesNoChange', 'evidence': 'In conclusion, the G-463A polymorphism of MPO was statistically associated with AD in a gender-specific manner. However, given the low significance of P value we suggest no causal effect of the MPO gene in AD, as also evidenced in a recent meta-analysis.', 'citation': {'type': 'PubMed', 'reference': '12946561'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"amyloid-beta\"), p(HGNC:NOS3), p(HGNC:PIN1)), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"amyloid-beta\"), p(HGNC:NOS3), p(HGNC:PIN1)), p(HGNC:NOS3)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"amyloid-beta\"), p(HGNC:NOS3), p(HGNC:PIN1)), p(HGNC:PIN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:NOS3), p(HGNC:PIN1)), p(HGNC:NOS3)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:NOS3), p(HGNC:PIN1)), p(HGNC:PIN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for a(CHEBI:losartan), a(CHEBI:\"angiotensin receptor antagonist\")\n",
      "WARNING:root:  with edge data {'line': 22765, 'relation': 'isA', 'evidence': \"In studies of dementias and Alzheimer's disease (AD), some studies have shown that antihypertensive drugs, including angiotensin-converting enzyme inhibitors, have some moderate effects on cognitive decline, but that the angiotensin receptor antagonist losartan has a significantly beneficial effect.\", 'citation': {'type': 'PubMed', 'name': 'Expert Opin Ther Targets. 2004 Feb;8(1):7-14', 'reference': '14996614'}, 'annotations': {'Subgraph': {'Renin-angiotensin subgraph': True}, 'Disease': {\"Alzheimer's disease\": True, 'dementia': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:GSTP1), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 24522, 'relation': 'causesNoChange', 'evidence': 'In conclusion, the involvement of GSTP1 alleles in individual susceptibility to AD was not confirmed as statistically significant in the tested Croatian Caucasian population.', 'citation': {'type': 'PubMed', 'name': 'Clin Chem Lab Med. 2004 Mar;42(3):334-9', 'reference': '15080568'}, 'annotations': {'Subgraph': {'Glutathione reductase subgraph': True}}}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APOE), p(HGNC:GSTP1)), p(HGNC:APOE)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APOE), p(HGNC:GSTP1)), p(HGNC:GSTP1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for a(CHEBI:melatonin), a(CHEBI:antioxidant)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 24667, 'relation': 'isA', 'evidence': 'The pineal product melatonin has remarkable antioxidant properties.', 'citation': {'type': 'PubMed', 'reference': '16179266'}}\n",
      "WARNING:root:No converter found for a(CHEBI:melatonin), path(MESHD:\"Parkinson Disease\")\n",
      "WARNING:root:  with edge data {'line': 24715, 'relation': 'causesNoChange', 'evidence': \"Therapeutic trials with melatonin have been effective in slowing the progression of Alzheimer's disease but not of Parkinson's disease.\", 'citation': {'type': 'PubMed', 'reference': '16179266'}, 'annotations': {'MeSHDisease': {'Neurodegenerative Diseases': True}, 'Disease': {\"Alzheimer's disease\": True, \"Parkinson's disease\": True}, 'Species': {'9606': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for complex(a(CHEBI:donepezil), a(CHEBI:memantine)), p(HGNC:GSR)\n",
      "WARNING:root:  with edge data {'line': 24655, 'relation': 'causesNoChange', 'evidence': 'Depending on the treatment received, a distinct inflammatory and oxidative stress profile was observed: in Rivastigmine-treated group, IL6 levels were 47% lower than the average value of the remaining AD patients; homocysteine and glutathione reductase were statistically unchanged in the Rivastigmine and Donepezil-Memantine, respectively Donepezil group.', 'citation': {'type': 'PubMed', 'name': 'Food Chem Toxicol. 2013 Nov;61:209-14', 'reference': '23871825'}, 'annotations': {'Species': {'9606': True}, 'Subgraph': {'Glutathione reductase subgraph': True}}}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:SOD1)), p(HGNC:SOD1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:SOD1)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for a(CHEBI:bosentan), a(CHEBI:\"endothelin receptor antagonist\")\n",
      "WARNING:root:  with edge data {'line': 25086, 'relation': 'isA', 'evidence': 'It has already been demonstrated that the endothelin receptor antagonist bosentan, preserves aortic and carotid endothelial function in Tg2576 mice, and our findings suggest that endothelin receptor antagonists may be beneficial in maintaining CBF in AD.', 'citation': {'type': 'PubMed', 'reference': '21193044'}, 'annotations': {'Subgraph': {'Endothelin subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CDKN1B), p(HGNC:RB1)), p(HGNC:CDKN1B)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CDKN1B), p(HGNC:RB1)), p(HGNC:RB1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:PRKCD, frag(\"?\", \"38kD\")), p(HGNC:PRKCD, frag(\"?\", \"41kD\"))), p(HGNC:PRKCD)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:PRKCD, frag(\"?\", \"38kD\")), p(HGNC:PRKCD, frag(\"?\", \"41kD\"))), p(HGNC:PRKCD)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(MGI:Psen1), p(MGI:Psen2)), p(MGI:Psen1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(MGI:Psen1), p(MGI:Psen2)), p(MGI:Psen2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(FPLX:NFkappaB), p(HGNC:NFKB1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(FPLX:NFkappaB), p(HGNC:NFKB2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRA1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRA2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRA3)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRA4)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRA5)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRA6)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRB1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRB2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRB3)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRG1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRG2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRG3)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRD)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRE)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRP)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(GFAM:\"Gamma-aminobutyric acid type A receptor subunits\"), p(HGNC:GABRQ)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(MGI:Xiap), complex(a(CHEBI:ATP), p(MGI:Apaf1), p(MGI:Cycs))\n",
      "WARNING:root:  with edge data {'line': 28277, 'relation': 'causesNoChange', 'evidence': \"Caspase-9 activation is mainly triggered by cytochrome c release from the mitochondria, which occurs at the asymptomatic stage prior to disease onset (Guebetagan et al., 2001). Cytochrome c, together with ATP/ADP, Apaf-1 and procaspase-9, forms a complex termed `apoptosome', in which caspase-9 is activated. Caspase-9 then cleaves procaspase-3 to generate active caspase-3. Both caspase-9 and caspase-3 cleave procaspase-9 to form an `amplication loop' of caspase-9 activation. XIAP does not inhibit `apoptosome' formation and its upstream events, but suppresses the downstream `amplibetacation loop' by inhibition of caspase-9 and -3. Therefore, the activation of caspase-9 preceded by cytochrome c release can occur in the presence of a potent caspase-9 inhibitor XIAP and be considered an indicator of disease onset, regardless of the level of caspase-9.\", 'citation': {'type': 'PubMed', 'name': 'EMBO J. 2003 Dec 15;22(24):6665-74', 'reference': '14657037'}, 'annotations': {'Subgraph': {'Caspase subgraph': True, 'XIAP subgraph': True, 'Electron transport chain': True}, 'Species': {'10090': True}}}\n",
      "WARNING:root:No converter found for composite(p(HGNC:ABL1), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\")), p(HGNC:ABL1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:ABL1), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\")), p(INTERPRO:\"Amyloidogenic glycoprotein, intracellular domain, conserved site\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for a(CHEBI:\"protectin D1\"), a(CHEBI:\"docosahexaenoic acid\")\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 30898, 'relation': 'isA', 'evidence': \"Neuroprotectin D1 (NPD1) is a stereoselective mediator derived from the omega-3 essential fatty acid docosahexaenoic acid (DHA) with potent inflammatory resolving and neuroprotective bioactivity. NPD1 reduces Abeta42 peptide release from aging human brain cells and is severely depleted in Alzheimer's disease (AD) brain.\", 'citation': {'type': 'PubMed', 'reference': '21246057'}, 'annotations': {'Subgraph': {'Inflammatory response subgraph': True, 'Neuroprotection subgraph': True, 'Non-amyloidogenic subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"protectin D1\"), p(HGNC:PPP2CA)), a(CHEBI:\"protectin D1\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"protectin D1\"), p(HGNC:PPP2CA)), p(HGNC:PPP2CA)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"amyloid-beta\"), p(HGNC:CSF1)), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"amyloid-beta\"), p(HGNC:CSF1)), p(HGNC:CSF1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IFNG), p(HGNC:IL1B)), p(HGNC:IFNG)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IFNG), p(HGNC:IL1B)), p(HGNC:IL1B)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(SFAM:\"NTRK Family\"), p(HGNC:NTRK3)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"NTRK Family\"), p(HGNC:NTRK2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"NTRK Family\"), p(HGNC:NTRK1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IFNG), p(HGNC:IL1B), p(HGNC:TNF)), p(HGNC:IFNG)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IFNG), p(HGNC:IL1B), p(HGNC:TNF)), p(HGNC:IL1B)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IFNG), p(HGNC:IL1B), p(HGNC:TNF)), p(HGNC:TNF)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"2-oxoglutaric acid\")), products(a(CHEBI:\"succinyl-CoA\"))), a(CHEBI:\"2-oxoglutaric acid\")\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"2-oxoglutaric acid\")), products(a(CHEBI:\"succinyl-CoA\"))), a(CHEBI:\"succinyl-CoA\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:PSEN1), p(HGNC:PSEN2)), p(HGNC:PSEN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:PSEN1), p(HGNC:PSEN2)), p(HGNC:PSEN2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP, frag(\"672_713\")), p(HGNC:PSEN1), p(HGNC:PSEN2)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CABIN1), p(HGNC:MAPK14), p(SFAM:\"CAMK2 Family\")), p(HGNC:CABIN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CABIN1), p(HGNC:MAPK14), p(SFAM:\"CAMK2 Family\")), p(HGNC:MAPK14)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CABIN1), p(HGNC:MAPK14), p(SFAM:\"CAMK2 Family\")), p(SFAM:\"CAMK2 Family\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:PSEN1), p(HGNC:PSEN2)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:PSEN1), p(HGNC:PSEN2)), p(HGNC:PSEN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:PSEN1), p(HGNC:PSEN2)), p(HGNC:PSEN2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:AXIN1), p(HGNC:AXIN2)), p(HGNC:AXIN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:AXIN1), p(HGNC:AXIN2)), p(HGNC:AXIN2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CSNK1G1), p(HGNC:CSNK1G3)), p(HGNC:CSNK1G1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:CSNK1G1), p(HGNC:CSNK1G3)), p(HGNC:CSNK1G3)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:PSEN1), p(HGNC:RAC1)), p(HGNC:PSEN1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:PSEN1), p(HGNC:RAC1)), p(HGNC:RAC1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:PSEN2), p(HGNC:RAC1)), p(HGNC:PSEN2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:PSEN2), p(HGNC:RAC1)), p(HGNC:RAC1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:DOCK3), p(HGNC:MAP3K5), p(HGNC:RAC1)), p(HGNC:DOCK3)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:DOCK3), p(HGNC:MAP3K5), p(HGNC:RAC1)), p(HGNC:MAP3K5)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:DOCK3), p(HGNC:MAP3K5), p(HGNC:RAC1)), p(HGNC:RAC1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:RPS6KA1), p(HGNC:RPS6KA4), p(HGNC:RPS6KA5)), p(HGNC:RPS6KA1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:RPS6KA1), p(HGNC:RPS6KA4), p(HGNC:RPS6KA5)), p(HGNC:RPS6KA4)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:RPS6KA1), p(HGNC:RPS6KA4), p(HGNC:RPS6KA5)), p(HGNC:RPS6KA5)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(SFAM:\"AKT Family\"), p(SFAM:\"PIK3C Class IA Family\")), p(SFAM:\"AKT Family\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(SFAM:\"AKT Family\"), p(SFAM:\"PIK3C Class IA Family\")), p(SFAM:\"PIK3C Class IA Family\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"copper(2+)\")), products(a(CHEBI:\"copper(1+)\"))), a(CHEBI:\"copper(2+)\")\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"copper(2+)\")), products(a(CHEBI:\"copper(1+)\"))), a(CHEBI:\"copper(1+)\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:NCAM1)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:NCAM1)), p(HGNC:NCAM1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:NCAM2)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:NCAM2)), p(HGNC:NCAM2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:ABL1), p(HGNC:APP)), p(HGNC:ABL1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:No converter found for composite(p(HGNC:ABL1), p(HGNC:APP)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:RELN)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:RELN)), p(HGNC:RELN)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(FPLX:Notch)), products(a(HBP:\"Notch intracellular domain\"))), p(FPLX:Notch)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(FPLX:Notch)), products(a(HBP:\"Notch intracellular domain\"))), a(HBP:\"Notch intracellular domain\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(a(HBP:\"YENPTY endocytosis motif (APP)\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(a(HBP:\"YENPTY endocytosis motif (APP)\"))), a(HBP:\"YENPTY endocytosis motif (APP)\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:GGA1), p(HGNC:PACS1), p(HGNC:SORL1)), p(HGNC:GGA1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:GGA1), p(HGNC:PACS1), p(HGNC:SORL1)), p(HGNC:PACS1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:GGA1), p(HGNC:PACS1), p(HGNC:SORL1)), p(HGNC:SORL1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:GGA2), p(HGNC:PACS1), p(HGNC:SORL1)), p(HGNC:GGA2)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:GGA2), p(HGNC:PACS1), p(HGNC:SORL1)), p(HGNC:PACS1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:GGA2), p(HGNC:PACS1), p(HGNC:SORL1)), p(HGNC:SORL1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:GGA3), p(HGNC:PACS1), p(HGNC:SORL1)), p(HGNC:GGA3)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:GGA3), p(HGNC:PACS1), p(HGNC:SORL1)), p(HGNC:PACS1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:GGA3), p(HGNC:PACS1), p(HGNC:SORL1)), p(HGNC:SORL1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:LAMB1)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:LAMB1)), p(HGNC:LAMB1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:COL9A1)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:COL9A1)), p(HGNC:COL9A1)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:GRIN2A)), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:APP), p(HGNC:GRIN2A)), p(HGNC:GRIN2A)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:KAT8), p(INTERPRO:\"Histone acetyltransferase domain, MYST-type\")\n",
      "WARNING:root:  with edge data {'line': 45192, 'relation': 'isA', 'evidence': 'Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3ÃƒÅ¸, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes', 'citation': {'type': 'PubMed', 'name': 'BMB Rep. 2010 Oct;43(10):656-63.', 'reference': '21034527'}, 'annotations': {'Published': {'CDR story': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(p(HGNC:APP, frag(\"?\")))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(p(HGNC:APP, frag(\"?\")))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(a(HBP:\"sAPP-beta\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(HGNC:APP)), products(a(HBP:\"sAPP-beta\"))), a(HBP:\"sAPP-beta\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:heme)), products(a(CHEBI:\"carbon monoxide\"), a(CHEBI:\"iron atom\"), a(CHEBI:biliverdin))), a(CHEBI:heme)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:heme)), products(a(CHEBI:\"carbon monoxide\"), a(CHEBI:\"iron atom\"), a(CHEBI:biliverdin))), a(CHEBI:\"carbon monoxide\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:heme)), products(a(CHEBI:\"carbon monoxide\"), a(CHEBI:\"iron atom\"), a(CHEBI:biliverdin))), a(CHEBI:\"iron atom\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:heme)), products(a(CHEBI:\"carbon monoxide\"), a(CHEBI:\"iron atom\"), a(CHEBI:biliverdin))), a(CHEBI:biliverdin)\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"nitric oxide\"), a(CHEBI:\"reactive oxygen species\"), a(MESH:D011453), a(MESHC:Chemokines), a(MESHC:Cytokines)), a(CHEBI:\"nitric oxide\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"nitric oxide\"), a(CHEBI:\"reactive oxygen species\"), a(MESH:D011453), a(MESHC:Chemokines), a(MESHC:Cytokines)), a(CHEBI:\"reactive oxygen species\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"nitric oxide\"), a(CHEBI:\"reactive oxygen species\"), a(MESH:D011453), a(MESHC:Chemokines), a(MESHC:Cytokines)), a(MESH:D011453)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"nitric oxide\"), a(CHEBI:\"reactive oxygen species\"), a(MESH:D011453), a(MESHC:Chemokines), a(MESHC:Cytokines)), a(MESHC:Chemokines)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"nitric oxide\"), a(CHEBI:\"reactive oxygen species\"), a(MESH:D011453), a(MESHC:Chemokines), a(MESHC:Cytokines)), a(MESHC:Cytokines)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(MESHC:Chemokines), a(MESHC:Cytokines)), a(MESHC:Chemokines)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(MESHC:Chemokines), a(MESHC:Cytokines)), a(MESHC:Cytokines)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"fatty acid\"), a(CHEBI:icosanoid), a(CHEBI:prostaglandin), a(MESHC:\"Reactive Oxygen Species\"), p(HGNC:PLA2G7)), a(CHEBI:\"fatty acid\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"fatty acid\"), a(CHEBI:icosanoid), a(CHEBI:prostaglandin), a(MESHC:\"Reactive Oxygen Species\"), p(HGNC:PLA2G7)), a(CHEBI:icosanoid)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"fatty acid\"), a(CHEBI:icosanoid), a(CHEBI:prostaglandin), a(MESHC:\"Reactive Oxygen Species\"), p(HGNC:PLA2G7)), a(CHEBI:prostaglandin)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:No converter found for composite(a(CHEBI:\"fatty acid\"), a(CHEBI:icosanoid), a(CHEBI:prostaglandin), a(MESHC:\"Reactive Oxygen Species\"), p(HGNC:PLA2G7)), a(MESHC:\"Reactive Oxygen Species\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"fatty acid\"), a(CHEBI:icosanoid), a(CHEBI:prostaglandin), a(MESHC:\"Reactive Oxygen Species\"), p(HGNC:PLA2G7)), p(HGNC:PLA2G7)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for p(HGNC:CHI3L1), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 52683, 'relation': 'prognosticBiomarkerFor', 'evidence': 'Discovery and validation cohorts, showed higher mean CSF YKL-40 in very mild and mild AD-type dementia (Clinical Dementia Rating [CDR] 0.5 and 1) versus / control subjects (CDR 0) and PSP subjects. Importantly, CSF YKL-40/Abeta42 ratio predicted risk of developing cognitive impairment (CDR 0 to CDR > 0 conversion), as well / as the best CSF biomarkers identified to date, tau/Abeta42 and p-tau 181/Abeta42. Mean plasma YKL-40 was higher in CDR 0.5 and 1 versus CDR 0, and correlated with CSF / levels. YKL-40 immunoreactivity labeled astrocytes near a subset of amyloid plaques, implicating YKL-40 in the neuroinflammatory response to Abeta deposition./ CONCLUSIONS: These data demonstrate that YKL-40, a putative indicator of neuroinflammation, is elevated in AD and, together with Abeta42, has potential prognostic utility / as a biomarker for preclinical AD.', 'citation': {'type': 'PubMed', 'name': 'Biol Psychiatry. 2010 Nov 15;68(10):903-12. doi: 10.1016/j.biopsych.2010.08.025.', 'reference': '21035623'}, 'annotations': {'Confidence': {'Medium': True}, 'Subgraph': {'Inflammatory response subgraph': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:CHI3L1), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 52684, 'relation': 'biomarkerFor', 'evidence': 'Discovery and validation cohorts, showed higher mean CSF YKL-40 in very mild and mild AD-type dementia (Clinical Dementia Rating [CDR] 0.5 and 1) versus / control subjects (CDR 0) and PSP subjects. Importantly, CSF YKL-40/Abeta42 ratio predicted risk of developing cognitive impairment (CDR 0 to CDR > 0 conversion), as well / as the best CSF biomarkers identified to date, tau/Abeta42 and p-tau 181/Abeta42. Mean plasma YKL-40 was higher in CDR 0.5 and 1 versus CDR 0, and correlated with CSF / levels. YKL-40 immunoreactivity labeled astrocytes near a subset of amyloid plaques, implicating YKL-40 in the neuroinflammatory response to Abeta deposition./ CONCLUSIONS: These data demonstrate that YKL-40, a putative indicator of neuroinflammation, is elevated in AD and, together with Abeta42, has potential prognostic utility / as a biomarker for preclinical AD.', 'citation': {'type': 'PubMed', 'name': 'Biol Psychiatry. 2010 Nov 15;68(10):903-12. doi: 10.1016/j.biopsych.2010.08.025.', 'reference': '21035623'}, 'annotations': {'Confidence': {'Medium': True}, 'Subgraph': {'Inflammatory response subgraph': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:CHI3L1), path(MESHD:Inflammation)\n",
      "WARNING:root:  with edge data {'line': 52663, 'relation': 'biomarkerFor', 'evidence': \"Cerebrospinal fluid YKL-40 has been described as a marker of glial inflammation. We aimed to study the relationship between YKL-40 and brain structure and / its interactions with core Alzheimer's disease (AD) biomarkers. We measured cortical thickness (CTh) and cerebrospinal fluid biomarkers (amyloid-beta 1-42 [Abeta42], total / tau, p-tau, and YKL-40) of 80 cognitively normal controls and 27 patients with amnestic mild cognitive impairment. Subjects were classified as Abeta42+ (<550 pg/mL) or / Abeta42- (>550 pg/mL). CTh difference maps were derived from the interaction and correlation analyses in the whole sample and within clinical groups. There was a strong / correlation between YKL-40 and markers of neurodegeneration (total tau and p-tau). In the whole sample, we found a negative correlation between YKL-40 and CTh in AD / vulnerable areas in Abeta42+ subjects but not in Abeta42 participants. Our results suggest that YKL-40 could track the inflammatory processes associated to tau-related / neurodegeneration in the presence of the AD pathophysiological process.\", 'citation': {'type': 'PubMed', 'name': 'Neurobiol Aging. 2015 Jun;36(6):2018-23. doi: 10.1016/j.neurobiolaging.2015.03.001. Epub 2015 Mar 9.', 'reference': '25865441'}, 'annotations': {'Confidence': {'Medium': True}, 'Subgraph': {'Inflammatory response subgraph': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"8-hydroxy-2'-deoxyguanosine\"), bp(MESHPP:\"Oxidative Stress\")\n",
      "WARNING:root:  with edge data {'line': 52969, 'relation': 'biomarkerFor', 'evidence': \" 8-oxo-dG is widely used as biomarker of oxidative DNA damage due to demethylation. 8-dihydro-2 ÃƒÅ’Ã¯Â¿Â½'-deoxyguanosine (8-oxo-dG), a general marker of oxidative stress\", 'citation': {'type': 'PubMed', 'reference': '19245828'}, 'annotations': {'Species': {'10090': True}, 'Subgraph': {'Reactive oxygen species subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"(24S)-24-hydroxycholesterol\"), path(MESHD:\"Nerve Degeneration\")\n",
      "WARNING:root:  with edge data {'line': 47561, 'relation': 'biomarkerFor', 'evidence': \" Glial fibrillary acidic protein and antibodies in CSF may be a marker for severe neurodegeneration. CSF concentrations of the oxidative stress markers 3-nitrotyrosine, 8-hydroxy-2'-deoxyguanosine and isoprostanes are increased in AD patients. Serum 24S-OH-cholesterol may be an early whereas glial fibrillary acidic protein autoantibody level may be a late marker for neurodegeneration. To date, serum alpha(1)-Antichymotripsin concentration is the most convincing marker for CNS inflammation. Increased serum homocysteine concentrations have also been consistently reported in AD\", 'citation': {'type': 'PubMed', 'name': 'Neurobiol Aging. 2002 Jul-Aug;23(4):485-508.', 'reference': '12009495'}, 'annotations': {'Subgraph': {'Response to oxidative stress': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"L-citrulline\")), products(a(CHEBI:\"L-arginine\"))), a(CHEBI:\"L-citrulline\")\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(a(CHEBI:\"L-citrulline\")), products(a(CHEBI:\"L-arginine\"))), a(CHEBI:\"L-arginine\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for p(HGNC:CNR1), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'line': 55907, 'relation': 'causesNoChange', 'evidence': 'Eleven AD patients and 7 healthy volunteers (HV) underwent combined [Â¹â�¸F]MK-9470 PET and [Â¹Â¹C]PIB PET scans to assess CBâ‚�R availability and amyloid deposition, respectively, and T1 volumetric MRI for partial volume correction. We found no difference in CBâ‚�R availability between AD and HV, VOI-based fractional uptake values (FUR) were 0.043Â±0.01 for AD and 0.045Â±0.01 for controls (p=0.9). CBâ‚�R availability did not correlate with neuropsychological test scores and was not modulated by ApoE genotype. As expected, global [Â¹Â¹C]PIB SUVR (standardized uptake value ratio) was increased in AD (SUVR 1.9Â±0.3) compared to HV (1.2Â±0.1) with p<0.001, but no correlation was found between amyloid beta (Abeta) deposition and CBâ‚�R availability.', 'citation': {'type': 'PubMed', 'name': 'Eur Neuropsychopharmacol. 2014 Feb;24(2):242-50. doi: 10.1016/j.euroneuro.2013.10.002. Epub 2013 Oct 17.', 'reference': '24189376'}, 'annotations': {'NIFT': {'Volumetric MRI': True}}}\n",
      "WARNING:root:No converter found for complex(p(MGI:Lat2), p(MGI:Runx1t1)), p(MGI:Lat2)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 49477, 'relation': 'causesNoChange', 'evidence': 'However, the enhanced binding of Runx1t1 to the LAT2 promoter could not repress the LAT2 expression when the BV2 microglia cells were treated with HDACi, indicating that Runx1t1 requires HDACs to transcriptionally repress the expression of LAT2.In conclusion, it is suggested that Runx1t1 controls proliferation and the neurotoxic effect of microglia by epigenetically regulating Cdk4 and LAT2 via its interaction with HDACs.', 'citation': {'type': 'PubMed', 'name': 'PloS one; Vol. 9; Iss. 2', 'reference': '24586690'}, 'annotations': {'MeSHAnatomy': {'Microglia': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for p(MGI:Vegfa), path(MESHD:\"Brain Edema\")\n",
      "WARNING:root:  with edge data {'line': 50462, 'relation': 'causesNoChange', 'evidence': 'Exogenous application of VEGF can increase the permeability of the BBB without causing brain edema.', 'citation': {'type': 'PubMed', 'name': 'PLoS One. 2014 Feb 14;9(2):e86407. doi: 10.1371/journal.pone.0086407. eCollection 2014.', 'reference': '24551038'}, 'annotations': {'Species': {'10090': True}, 'MeSHDisease': {'Brain Edema': True}, 'MeSHAnatomy': {'Brain': True}, 'Subgraph': {'Vascular endothelial growth factor subgraph': True}, 'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for rxn(reactants(p(MGI:App)), products(a(CHEBI:\"amyloid-beta\"))), p(MGI:App)\n",
      "WARNING:root:  with edge data {'relation': 'hasReactant'}\n",
      "WARNING:root:No converter found for rxn(reactants(p(MGI:App)), products(a(CHEBI:\"amyloid-beta\"))), a(CHEBI:\"amyloid-beta\")\n",
      "WARNING:root:  with edge data {'relation': 'hasProduct'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IL1B), p(HGNC:IL6)), p(HGNC:IL1B)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IL1B), p(HGNC:IL6)), p(HGNC:IL6)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IL1B), p(HGNC:OSM)), p(HGNC:IL1B)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IL1B), p(HGNC:OSM)), p(HGNC:OSM)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for a(CHEBI:\"lead(0)\"), p(MGI:App)\n",
      "WARNING:root:  with edge data {'line': 52887, 'relation': 'causesNoChange', 'evidence': 'We observed that APP mRNA expression was transiently induced in neonates, but exhibited a delayed overexpression 20 months after exposure to Pb had ceased. This upregulation in APP mRNA expression was commensurate with a rise in activity of the transcription factor Sp1, one of the regulators of the APP gene. Furthermore, the increase in APP gene expression in old age was accompanied by an elevation in APP and its amyloidogenic Abeta product. In contrast, APP expression, Sp1 activity, as well as APP and Abeta protein levels were unresponsive to Pb exposure during old age.', 'citation': {'type': 'PubMed', 'name': 'J Neurosci. 2005 Jan 26;25(4):823-9.', 'reference': '15673661'}, 'annotations': {'Species': {'10090': True}, 'Subgraph': {'Epigenetic modification subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"lead(0)\"), p(MGI:Sp1)\n",
      "WARNING:root:  with edge data {'line': 52893, 'relation': 'causesNoChange', 'evidence': 'We observed that APP mRNA expression was transiently induced in neonates, but exhibited a delayed overexpression 20 months after exposure to Pb had ceased. This upregulation in APP mRNA expression was commensurate with a rise in activity of the transcription factor Sp1, one of the regulators of the APP gene. Furthermore, the increase in APP gene expression in old age was accompanied by an elevation in APP and its amyloidogenic Abeta product. In contrast, APP expression, Sp1 activity, as well as APP and Abeta protein levels were unresponsive to Pb exposure during old age.', 'citation': {'type': 'PubMed', 'name': 'J Neurosci. 2005 Jan 26;25(4):823-9.', 'reference': '15673661'}, 'annotations': {'Species': {'10090': True}, 'Subgraph': {'Epigenetic modification subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for g(HGNC:L1RE1), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 53466, 'relation': 'causesNoChange', 'evidence': \"We did not find differences in LINE-1 methylation levels between patients with Alzheimer's disease and control participants\", 'citation': {'type': 'PubMed', 'name': 'Am J Alzheimers Dis Other Demen. 2014 Feb;29(1):50-3. doi: 10.1177/1533317513505132. Epub 2013 Oct 27.', 'reference': '24164934'}, 'annotations': {'Race': {'Colombian': True}, 'Cell': {'blood cell': True}, 'DiseaseState': {'Late-onset AD': True}, 'Subgraph': {'Epigenetic modification subgraph': True}}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"trichostatin A\"), a(CHEBI:\"EC 3.5.1.98 (histone deacetylase) inhibitor\")\n",
      "WARNING:root:  with edge data {'line': 53800, 'relation': 'isA', 'evidence': 'HDAC inhibitor trichostatin A (TSA) resulted in prolonged p65 acetylation ', 'citation': {'type': 'PubMed', 'name': 'Neurobiol Learn Mem. 2011 Jul;96(1):68-78. doi: 10.1016/j.nlm.2011.03.001. Epub 2011 Mar 16.', 'reference': '21419233'}}\n",
      "WARNING:root:No converter found for a(CHEBI:\"B vitamin\"), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 69185, 'relation': 'causesNoChange', 'evidence': 'High-dose B vitamin supplementation in individuals with normal levels of B vitamins was effective in reducing homocysteine levels. This regimen of high-dose B vitamin supplements does not slow cognitive decline in individuals with mild to moderate AD.', 'citation': {'type': 'PubMed', 'reference': '18854539'}}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"9-cis-retinoic acid\"), a(CHEBI:rosiglitazone)), a(CHEBI:\"9-cis-retinoic acid\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"9-cis-retinoic acid\"), a(CHEBI:rosiglitazone)), a(CHEBI:rosiglitazone)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IFNG), p(HGNC:IL5), p(HGNC:TNF)), p(HGNC:IFNG)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IFNG), p(HGNC:IL5), p(HGNC:TNF)), p(HGNC:IL5)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:IFNG), p(HGNC:IL5), p(HGNC:TNF)), p(HGNC:TNF)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:dexamethasone), p(HGNC:CD28)), a(CHEBI:dexamethasone)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:dexamethasone), p(HGNC:CD28)), p(HGNC:CD28)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:estradiol), a(CHEBI:progesterone)), a(CHEBI:estradiol)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:estradiol), a(CHEBI:progesterone)), a(CHEBI:progesterone)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for a(CHEBI:\"heparan sulfate proteoglycan\"), p(HGNC:SDC1)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(CHEBI:\"heparan sulfate proteoglycan\"), p(HGNC:SDC2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(CHEBI:\"heparan sulfate proteoglycan\"), p(HGNC:SDC3)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(CHEBI:\"heparan sulfate proteoglycan\"), p(HGNC:SDC4)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for a(CHEBI:\"heparan sulfate proteoglycan\"), a(HBP:\"huntingtin aggregates\")\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:  with edge data {'line': 66638, 'relation': 'causesNoChange', 'evidence': 'Taken together, these data indicate that tau and alpha-synuclein use a similar mechanism for uptake based on binding HSPGs, whereas Htt exon 1 fibril uptake is distinct.', 'citation': {'type': 'PubMed', 'name': 'Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47.', 'reference': '23898162'}, 'annotations': {'Confidence': {'Medium': True}}}\n",
      "WARNING:root:No converter found for bp(GOBP:\"Wnt signaling pathway, planar cell polarity pathway\"), bp(GOBP:\"non-canonical Wnt signaling pathway\")\n",
      "WARNING:root:  with edge data {'line': 67356, 'relation': 'isA', 'evidence': 'To further elucidate how the clusterin-dependent induction of Dkk1 by Abeta mediates neurotoxicity, we measured the effects of Abeta and Dkk1 protein on whole-genome expression in primary neurons, finding a common pathway suggestive of activation of wnt–planar cell polarity (PCP)–c-Jun N-terminal kinase (JNK) signalling leading to the induction of genes including EGR1 (early growth response-1), NAB2 (Ngfi-A-binding protein-2) and KLF10 (Krüppel-like factor-10) that, when individually silenced, protected against Abeta neurotoxicity and/or tau phosphorylation. To summarise, we show that Ab-induced neurotoxicity, including tau phosphorylation at specific epitopes, is via the CLU-dependent induction of Dkk1, with Dkk1 then driving wnt–PCP signalling to increase expression of genes that we have identified and shown to be necessary mediators of these pathological processes.', 'citation': {'type': 'PubMed', 'name': 'Mol Psychiatry. 2014 Jan;19(1):88-98. doi: 10.1038/mp.2012.163. Epub 2012 Nov 20.', 'reference': '23164821'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'MeSHAnatomy': {'Neurons': True}, 'Confidence': {'High': True}, 'Subgraph': {'DKK1 subgraph': True, 'Tau protein subgraph': True, 'Gamma secretase subgraph': True}}}\n",
      "WARNING:root:No converter found for bp(GOBP:\"non-canonical Wnt signaling pathway\"), bp(GOBP:\"Wnt signaling pathway\")\n",
      "WARNING:root:  with edge data {'line': 67357, 'relation': 'isA', 'evidence': 'To further elucidate how the clusterin-dependent induction of Dkk1 by Abeta mediates neurotoxicity, we measured the effects of Abeta and Dkk1 protein on whole-genome expression in primary neurons, finding a common pathway suggestive of activation of wnt–planar cell polarity (PCP)–c-Jun N-terminal kinase (JNK) signalling leading to the induction of genes including EGR1 (early growth response-1), NAB2 (Ngfi-A-binding protein-2) and KLF10 (Krüppel-like factor-10) that, when individually silenced, protected against Abeta neurotoxicity and/or tau phosphorylation. To summarise, we show that Ab-induced neurotoxicity, including tau phosphorylation at specific epitopes, is via the CLU-dependent induction of Dkk1, with Dkk1 then driving wnt–PCP signalling to increase expression of genes that we have identified and shown to be necessary mediators of these pathological processes.', 'citation': {'type': 'PubMed', 'name': 'Mol Psychiatry. 2014 Jan;19(1):88-98. doi: 10.1038/mp.2012.163. Epub 2012 Nov 20.', 'reference': '23164821'}, 'annotations': {'Disease': {\"Alzheimer's disease\": True}, 'MeSHAnatomy': {'Neurons': True}, 'Confidence': {'High': True}, 'Subgraph': {'DKK1 subgraph': True, 'Tau protein subgraph': True, 'Gamma secretase subgraph': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:TUBB6), path(MESHD:\"Alzheimer Disease\")\n",
      "WARNING:root:  with edge data {'line': 67911, 'relation': 'biomarkerFor', 'evidence': \"Keratin 9 was recently identified as an important component of a biomarker panel which demonstrated a high diagnostic accuracy (87%) for Alzheimer's disease (AD).\", 'citation': {'type': 'PubMed', 'name': 'Scientific reports', 'reference': '26973255'}, 'annotations': {'Subgraph': {'Regulation of actin cytoskeleton subgraph': True}, 'Confidence': {'High': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:ARHGEF5), p(HGNC:RAC1)\n",
      "WARNING:root:  with edge data {'line': 67939, 'relation': 'causesNoChange', 'evidence': ' Arhgef5 can strongly activate RhoA and RhoB and weakly RhoC and RhoG, but not Rac1, RhoQ, RhoD, or RhoV, in transfected human embryonic kidney 293 cells.', 'citation': {'type': 'PubMed', 'name': ' The Journal of biological chemistry', 'reference': '19713215'}, 'annotations': {'Subgraph': {'RhoA subgraph': True}, 'CellLine': {'HEK293': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:ARHGEF5), p(HGNC:RHOD)\n",
      "WARNING:root:  with edge data {'line': 67940, 'relation': 'causesNoChange', 'evidence': ' Arhgef5 can strongly activate RhoA and RhoB and weakly RhoC and RhoG, but not Rac1, RhoQ, RhoD, or RhoV, in transfected human embryonic kidney 293 cells.', 'citation': {'type': 'PubMed', 'name': ' The Journal of biological chemistry', 'reference': '19713215'}, 'annotations': {'Subgraph': {'RhoA subgraph': True}, 'CellLine': {'HEK293': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:ARHGEF5), p(HGNC:RHOQ)\n",
      "WARNING:root:  with edge data {'line': 67941, 'relation': 'causesNoChange', 'evidence': ' Arhgef5 can strongly activate RhoA and RhoB and weakly RhoC and RhoG, but not Rac1, RhoQ, RhoD, or RhoV, in transfected human embryonic kidney 293 cells.', 'citation': {'type': 'PubMed', 'name': ' The Journal of biological chemistry', 'reference': '19713215'}, 'annotations': {'Subgraph': {'RhoA subgraph': True}, 'CellLine': {'HEK293': True}}}\n",
      "WARNING:root:No converter found for p(HGNC:ARHGEF5), p(HGNC:RHOV)\n",
      "WARNING:root:  with edge data {'line': 67942, 'relation': 'causesNoChange', 'evidence': ' Arhgef5 can strongly activate RhoA and RhoB and weakly RhoC and RhoG, but not Rac1, RhoQ, RhoD, or RhoV, in transfected human embryonic kidney 293 cells.', 'citation': {'type': 'PubMed', 'name': ' The Journal of biological chemistry', 'reference': '19713215'}, 'annotations': {'Subgraph': {'RhoA subgraph': True}, 'CellLine': {'HEK293': True}}}\n",
      "WARNING:root:No converter found for p(SFAM:\"RHO Family\"), p(HGNC:RHOQ)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"RHO Family\"), p(HGNC:RHOBTB2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"RHO Family\"), p(HGNC:RHOH)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"HES Family\"), p(HGNC:HES2)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"HES Family\"), p(HGNC:HES4)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for p(SFAM:\"HES Family\"), p(HGNC:HES5)\n",
      "WARNING:root:  with edge data {'relation': 'hasMember'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"Ibotenic acid\"), p(HGNC:APP, frag(\"672_713\"))), a(CHEBI:\"Ibotenic acid\")\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(a(CHEBI:\"Ibotenic acid\"), p(HGNC:APP, frag(\"672_713\"))), p(HGNC:APP)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:TNFRSF12A), p(HGNC:TNFRSF25)), p(HGNC:TNFRSF12A)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for composite(p(HGNC:TNFRSF12A), p(HGNC:TNFRSF25)), p(HGNC:TNFRSF25)\n",
      "WARNING:root:  with edge data {'relation': 'hasComponent'}\n",
      "WARNING:root:No converter found for g(DBSNP:rs7975232), bp(GOBP:cognition)\n",
      "WARNING:root:  with edge data {'line': 69039, 'relation': 'causesNoChange', 'evidence': 'More specifically, carriers of BamI and TaqI polymorphisms presented with worse cognitive functioning unlike carrier of the ApaI variant. Examination of ApaI and TaqI gene polymorphisms in 255 AD cases and 260 cognitively screened elderly controls revealed that the presence of each of these haplotypes was associated with the risk of AD.', 'citation': {'type': 'PubMed', 'reference': '27176073'}, 'annotations': {'Subgraph': {'Vitamin subgraph': True}, 'Confidence': {'High': True}}}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Nodes after edge reification 20720\n",
      "Edges after edge reification 32266\n"
     ]
    }
   ],
   "source": [
    "# graph = from_url(url[bel])\n",
    "graph = from_path(local)\n",
    "\n",
    "print(\"Starting nodes\", len(graph.nodes))\n",
    "print(\"Starting edges\", len(graph.edges))\n",
    "\n",
    "# Collapse all variants is removing also the pmod(X) from the BaseEntity\n",
    "collapse_all_variants(graph)\n",
    "# TODO collapse_to_genes removes the ptm information before converting\n",
    "# collapse_to_genes(graph)\n",
    "\n",
    "print(\"Nodes after collapse\", len(graph.nodes))\n",
    "print(\"Edges after collapse\", len(graph.edges))\n",
    "\n",
    "# Reify the edges\n",
    "rbg = assembler.reify_bel_graph(graph)\n",
    "\n",
    "print(\"Nodes after edge reification\", len(rbg.nodes))\n",
    "print(\"Edges after edge reification\", len(rbg.edges))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Assess the converted entity and predicate nodes."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Predicates\n",
      "{'correlatesTo': 7686, 'abundance': 5491, 'degradates': 156, 'activates': 640, 'translates': 490, 'hasComponent': 1670}\n",
      "Proteins 1496\n",
      "RNA      492\n",
      "Gene     493\n"
     ]
    }
   ],
   "source": [
    "qty_predicate = {}\n",
    "qty_prot, qty_rna, qty_gene = 0, 0, 0\n",
    "for i in rbg.nodes:\n",
    "    if isinstance(i, BaseEntity):\n",
    "        if isinstance(i, rna):\n",
    "            qty_rna += 1\n",
    "        elif isinstance(i, protein):\n",
    "            qty_prot += 1\n",
    "        elif isinstance(i, gene):\n",
    "            qty_gene += 1\n",
    "    else:\n",
    "        if rbg.nodes[i]['label'] in qty_predicate:\n",
    "            qty_predicate[rbg.nodes[i]['label']] += 1\n",
    "        else:\n",
    "            qty_predicate[rbg.nodes[i]['label']] = 1\n",
    "\n",
    "print(\"Predicates\")\n",
    "print(qty_predicate)\n",
    "\n",
    "print(f\"Proteins {qty_prot}\")\n",
    "print(f\"RNA      {qty_rna}\")\n",
    "print(f\"Gene     {qty_gene}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Adding PheWAS annotation (as attributes).\n",
    "\n",
    "### Load the links between Phenotype and genes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "PheWAS Catalog - generating Dict: 100%|█████████████████████████████████████| 215107/215107 [00:19<00:00, 10775.18it/s]\n"
     ]
    }
   ],
   "source": [
    "phewas_manager = bio2bel_phewascatalog.Manager()\n",
    "pw_dict = phewas_manager.to_dict()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Save the disease list into the graph"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "start_ind = len(rbg.nodes)\n",
    "phenotypes_list = set([phe for _list in pw_dict.values()\n",
    "                           for odds, phe in _list])\n",
    "# unique_phenotypes = set().union(*pw_dict.values())\n",
    "enum_phenotypes = enumerate(phenotypes_list, start=start_ind)\n",
    "att_mappings = {phenot: num for num, phenot in enum_phenotypes}\n",
    "\n",
    "annotated_graph = rbg.copy()\n",
    "phewas_utils.add_disease_attribute(annotated_graph, pw_dict)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Genarate the labels for classification."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "querying 1-146...done.\n",
      "Targets found in the network: 91\n"
     ]
    }
   ],
   "source": [
    "phewas_utils.download_for_disease('EFO_0000249', 'ot_entrez.txt')\n",
    "targets = phewas_utils.parse_gene_list('ot_entrez.txt', rbg)\n",
    "print('Targets found in the network:', len(targets))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Targets not present at the network"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'SCN11A', 'ADRA2C', 'HTR3B', 'MAOB', 'PDE3A', 'SCN8A', 'CUL4A', 'SCN10A', 'HTR2C', 'PGR', 'SLC6A2', 'CACNA1B', 'GNRHR', 'SCN1A', 'HTR3E', 'RBX1', 'SLC6A3', 'HTR3A', 'SCN5A', 'SLC6A4', 'DDB1', 'SLC5A2', 'ATP4A', 'HTR3D', 'DRD2', 'SCN7A', 'ADRA1A', 'PPARD', 'VKORC1', 'ALDH5A1', 'MAOA', 'ADRA1D', 'ADORA2B', 'ADORA1', 'DRD3', 'HTR3C', 'RARG', 'RARA', 'IFNAR2', 'ADRA2B', 'PAH', 'CRBN', 'ADRA1B', 'SCN9A', 'CACNA2D1', 'KIT', 'ADRA2A', 'HRH3', 'SCN2A', 'SCN3A', 'RXRB', 'SCN4A', 'ADORA3', 'CSF2RA', 'IMPA1'}\n"
     ]
    }
   ],
   "source": [
    "with open('ot_entrez.txt') as f:\n",
    "    alltargets = set(f.read().split())\n",
    "print(alltargets.difference(targets))\n",
    "# Targets found in the network: 86, without taking non causal correlations\n",
    "# Targets found in the network: 91, taking non causal correlations\n",
    "# missing targets were:\n",
    "\"\"\"'IMPA1', 'ADORA3', 'PDE3A', 'ADRA2A', 'GNRHR', 'ADRA1B', 'HTR3A', 'HTR3D', 'SCN8A', 'APH1B', 'CSF2RA', 'FAAH', 'ADRA2C', 'MAOA', 'SCN2A', 'ALDH5A1', 'AGTR1', 'DDB1', 'DRD3', 'SCN11A', 'SCN1A', 'HTR3C', 'VKORC1', 'CACNA1B', 'SV2A', 'SCN5A', 'PAH', 'SCN3A', 'SCN9A', 'SLC6A2', 'ADORA1', 'FGFR3', 'HTR2C', 'HTR3B', 'PGR', 'RXRB', 'ADRA1A', 'SCN4A', 'DRD2', 'ADORA2B', 'SCN10A', 'CUL4A', 'SLC6A3', 'RARG', 'RBX1', 'PPARD', 'IFNAR2', 'SLC5A2', 'ADRA1D', 'ADRA2B', 'HTR3E', 'MAOB', 'CRBN', 'KIT', 'RARA', 'ATP4A', 'HRH3', 'CACNA2D1', 'SCN7A', 'SLC6A4'\"\"\";"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Create adjacency list and labels files for GAT2VEC"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "import logging\n",
    "\n",
    "# Structure graph\n",
    "out_rbg = convert_node_labels_to_integers(annotated_graph, \n",
    "                                          # first_label=1, \n",
    "                                          label_attribute='old_label')\n",
    "write_adjlist(out_rbg, struct_file)\n",
    "\n",
    "# print(att_mappings)\n",
    "# Attribute graph\n",
    "phewas_utils.write_adj_file_attribute(out_rbg, attr_file, att_mappings)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "phewas_utils.write_labels_file(labels_file, out_rbg, targets)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
